M. Lynn Crismon, Pharm.D., FCCP, BCPP OFFICE ADDRESS …sites.utexas.edu/crismon/files/2015/03/Crismon-CV-160821.pdf · CURRICULUM VITAE M. Lynn Crismon, Pharm.D., FCCP, BCPP OFFICE

CURRICULUM VITAE

M. Lynn Crismon, Pharm.D., FCCP, BCPP

OFFICE ADDRESS

College of Pharmacy, Suite 5.112 The University of Texas at Austin 2409 University Ave. MC#A1900 Austin, Texas 78712 Telephone: (512) 471-3718 FAX: (512) 471-8783 e-mail: [email protected]

EDUCATION AND TRAINING

The University of Oklahoma College of Pharmacy Oklahoma City, Oklahoma 1969-1974 Bachelor of Science in Pharmacy United States Public Health Service Gallup Indian Medical Center Gallup, New Mexico 1974-1975 Residency in Hospital Pharmacy Practice The University of Texas at Austin and The University of Texas Health Science Center at San Antonio 1976-1979 Doctor of Pharmacy The University of Texas College of Pharmacy and San Antonio State Hospital 1978-1979 Residency in Psychiatric Pharmacy Practice Kennedy Institute for Ethics Georgetown University June 1981 NEH Summer Fellowship in Biomedical Ethics

BOARD CERTIFICATION AND LICENSURE

New Mexico State Board of Pharmacy, Certificate Number 3838, 1975 Texas State Board of Pharmacy, Certificate Number 22035, 1976 Diplomate of the American Board of Clinical Pharmacology, Certificate Number 96113, 1996 Board Certified Psychiatric Pharmacist, Board of Pharmaceutical Specialties, BCPP #499105, 1999. Recertified 2006, 2013.

M. Lynn Crismon, Pharm.D., FCCP, BCPP Curriculum Vitae

Page 2 August 2016

PROFESSIONAL EXPERIENCE

Academic Appointments July 1976 - June 1979 Doctor of Pharmacy Program and Clinical Psychiatric

Pharmacy. Residency. Research Project: Longitudinal Evaluation of Psychotropic Drug Use in Hospitalized Childhood Schizophrenics.

Major Professor: Larry Ereshefsky, Pharm.D. July 1977 - June 1979 Teaching Assistant, The University of Texas Health Science

Center at San Antonio and The University of Texas at Austin. September 1979 - August 1984 Assistant Professor, Clinical Division, College of Pharmacy,

The University of Texas at Austin, Austin, Texas September 1984 - August 1985 Assistant Dean, College of Pharmacy, The University of

Texas at Austin May 1985 - July 1986 Interim Head, Clinical Division at Austin, College of

Pharmacy, The University of Texas at Austin September 1985 - August 1986 Regents Fellow in Psychiatric Pharmacy, College of

Pharmacy, The University of Texas at Austin September 1984 - August 1991 Associate Professor, Clinical Division, College of Pharmacy,

The University of Texas at Austin June 1989 Visiting Professor, College of Arts, Science and Technology, July 1991 Kingston, Jamaica, W.I. September 1981 - 1992 Associate Member of the Graduate Faculty of the University

of Texas Health Science Center at San Antonio

July 1986 - August 1996 Head, Clinical Division at Austin, College of Pharmacy, The University of Texas at Austin

September 1986 – August 2004 Southwestern Drug Corporation Centennial Fellow in

Pharmacy, College of Pharmacy, The University of Texas at Austin

July 1981 - March 2004 Coordinator, Psychiatric Pharmacy Research and Education

Program, The University of Texas College of Pharmacy and Texas Department of Mental Health & Mental Retardation

January 2007 Visiting Professor, Institute of Mental Health, National

Health Group, Singapore, Singapore


Page 3 August 2016

September 1991 – Present Professor, College of Pharmacy, The University of Texas at Austin

Number of psychiatric pharmacy residents supervised: 35 Number of research fellows supervised: 11 Number of PhD graduates supervised: 1 Number of PhD student supervisory committees: 9 Number of MS graduates supervised: 5 Number of honors program students supervised: 7 March 2004 – Director, Psychiatric Pharmacy Programs, College of January 2007 Pharmacy, The University of Texas at Austin and affiliated

institutions. September 2004 – January 2007 Associate Dean for Clinical Programs, College of Pharmacy,

The University of Texas at Austin January – October 2007 Dean ad interim and James T. Doluisio Chair in Pharmacy,

College of Pharmacy, The University of Texas at Austin

December 2009 – 2014 Member of the Faculty, Psychiatry Residency Program and Child & Adolescent Psychiatry Fellowship Program, University of Texas Southwestern Medical Center – Austin, Seton Family of Hospitals

December 2014 – Present Member of the Faculty, Psychiatry Residency Program and

Child & Adolescent Psychiatry Fellowship Program, Dell Medical School, The University of Texas at Austin and Seton Family of Hospitals

September 2004 – Present Behren’s Inc. Centennial Professor in Pharmacy, Division of

Health Outcomes & Pharmacy Practice, The University of Texas at Austin

November 2007 – Present Dean and James T. Doluisio Chair in Pharmacy, College of

Pharmacy, The University of Texas at Austin Professional Practice Appointments May 1972 - October 1972 Extern pharmacist, Morrison Drug, Norman, Oklahoma October 1972 - March 1973 Extern pharmacist, University of Oklahoma Hospitals,

Oklahoma City, Oklahoma March 1973 - May 1974 Intern pharmacist, Hillcrest Osteopathic Hospital, Oklahoma

City, Oklahoma


Page 4 August 2016

June 1974 - June 1975 Pharmacy Resident, Commissioned Officer, USPHS Gallup Indian Medical Center, Gallup, New Mexico

May 1975 - June 1976 Deputy Chief of Pharmacy, Commissioned Officer, USPHS

Indian Hospital, Winslow, Arizona September 1983 - August 1984 Director, Clinical Pharmacology Services, Austin State

Hospital, Austin, Texas July 1988 - August 1989 Chief of Psychopharmacology, Healthcare Rehabilitation

Center, Austin, Texas August 1983 - August 1991 Clinical Pharmacology Consultant, Central Office, Texas

Department of Mental Health and Mental Retardation, Austin, Texas

August 1985 - 1998 Clinical Pharmacology Consultant and Member of the

Medical Staff, Healthcare Rehabilitation Center, Austin, Texas

January 1991 - January 1998 Director of Neuropsychiatry Research, Center for Clinical

Research, Austin Diagnostic Clinic, Austin, Texas August 1986 - 1998 Consultant, Psychiatric Hospital Medicare Certification

Program, Healthcare Financing Administration, U.S. Department of Health and Human Services

August 1985 - 1998 Clinical Pharmacology Consultant and Member of the

Medical Staff, Healthcare Rehabilitation Center, Austin, Texas

June 1996 - 2002 Co-Director, Texas Medication Algorithm Project (TMAP),

Texas Department of Mental Health and Mental Retardation, Austin, TX

November 1998 - 2002 Director, Children’s Medication Algorithm Project (CMAP),

Texas Department of Mental Health and Mental Retardation, Austin, TX

September 1979 - 2006 Clinical Pharmacology Consultant Member of the Medical

Staff, Austin State Hospital (ASH), Austin, Texas. September 1996 – 2006 Clinical Psychopharmacology Consultant, Office of the

Medical Director for Behavioral Health, Texas Department of State Health Services, Austin, TX


Page 5 August 2016

September 2003 – 2009 Member of the Faculty, Psychiatry Residency Programs, Austin Medical Education Program, Seton Family of Hospitals

Other Consultantships

Texas Association of Community Health Centers, 1986. Charter Lane Hospital, Austin, Texas, 1987-88. Oklahoma Department of Mental Health, Oklahoma City, Oklahoma, 1988 Attorney General's Office, State of Texas, 1988-90 Travis County Attorney’s Office, Austin, TX, 1994 Consultant, Magellan Behavioral Healthcare, 2001. Consultant, Medco Cost Containment, Inc., 1995 & 1997 – 2001. Consultant, University of Kansas School of Pharmacy, 2005. Member, Scientific Advisory Committee for the study entitled, Using Behavioral Science

to Modify Physicians' Practices. Division of Child Psychiatry, Columbia University, 2001- 2007.

Expert Witness, U.S. Attorney’s Office, 2011. Member, Steering Committee, Pediatric Psychopharmacology in Primary Care Minifellowship, REACH Institute, NYC, NY, 2007 – 2012 Member, Internal Advisory Panel, VISN 17 Center of Excellence for Research on

Returning War Veterans, Department of Veterans’ Affairs, Waco, TX., 2009 - 2013 Member, Accreditation Site Team, Pharmaceutical Society of Ireland, 2013 Consultant, University of Georgia College of Pharmacy, Medical College of Georgia

campus, 2013. Consultant, REACH Institute, NYC, NY, 2012 - present Consultant (pro bono), Texas Department of Family & Protective Services, 2007 – present. Site Team Surveyor, Accreditation Council on Pharmacy Education, 2010 – present Member, Board of Directors, Longhorn Village, Austin, TX, 2013 – present Chair, Advisory Board, RxWiki, Austin, TX, 2014 - present

RESEARCH ACTIVITIES Grants and Contracts Received as Principal or Co-Principal Investigator

Caffeine Effects on Schizophrenics' Mental Status (with Ereshefsky L). Mission Pharmaceuticals, 1980.

Haloperidol Tissue Levels in Mice, University Research Institute, $5300, 1981. Medical Ethics in Comparative Perspective, Humanities Seminar for Medical and Health Care

Teachers, Georgetown University, National Endowment for the Humanities, $1250, 1981. Double Blind, Placebo Controlled Comparison of the Antidepressant Indalpine and Imipramine

in Depressed Outpatients (with Childs A and Kastenholz KV), Kendle Research Associates, 1983-84.


Page 6 August 2016

Double Blind Comparison of the Long Term Safety and Efficacy of Indalpine and Imipramine in Depressed Outpatients (with Childs A and Kastenholz KV), Kendle Research Associates, 1984-85.

Fluoxetine: Fixed Dosage in Mild or Moderate Depression (with Kastenholz KV, and Childs

A), Feighner Research Institute, 1984-85. The Development of a Tool to Diagnose, Teach and Evaluate Clinical Decision-Making Skills in

Pharmacy Students (with Riffee W and Greer M), Project Quest, $12,000, 1985-86. Investigation of Thiothixene Plasma Concentration Response Relationship Utilizing a High

Performance Thin Layer Chromatography Assay and a New Neuroleptic Response Rating Scale (with Sommi RW and Davis C), University Research Institute, $5,000, 1986-87.

A Study to Compare the Single versus Multiple Dose Pharmacokinetics of Clozapine in

Psychiatric Inpatients (with Ereshefsky L [PI] and Saklad SR), Sandoz Research Institute, 1986-87.

Clinical Drug Research Center Development Grant, Central Texas Medical Foundation, $15,000,

1987-88. Tacrine in Persistent Vegetative State and Coma Arousal (with Stanley DA and Childs A),

American College of Clinical Pharmacy - Mead Johnson CNS Research Award, $5,000, 1989-90.

An Examination of Potential Non-linear Lithium Pharmacokinetics and the Determination of

Lithium Pharmacokinetic Parameters Using NONMEM (Jermain DM – fellow; Crismon -- mentor), ASHP Foundation Fellowship in Psychiatric Drug Therapy, $19,500, 1989-90.

Head Injury Research Grant (with Stanley DA and Childs A), Parke-Davis Pharmaceutical

Research Division, $15,000, 1989-90. Comparative Bioavailability of Aged vs. Fresh Furosemide Tablets with Different Dissolution

Characteristics (with Manning LW, Godley PJ, Sack, M, Davis P, and Doluisio JT), Hoechst-Roussel Pharmaceuticals, 1990.

Clinical Psychopharmacology Program Support, Multiple Donors, $4,538, 1986-91. Clinical Drug Research Center Development Grant (with Godley PJ and Sack MR), Austin

Diagnostic Clinic Center for Clinical Research, $67,600, 1989-91. Bioequivalence of Research vs. Market Formulations of Risperidone in Schizophrenic Patients

(with Ereshefsky L, Sack, M, Horton M, and ADC Center for Clinical Research), Janssen Research Foundation, 1991.

Development of Clinical Pharmacy Education and Services (with Smeeding J and Petry M),

Brackenridge Hospital, City of Austin, $264,550, 1986-92.


Page 7 August 2016

Development of Clinical Pharmacy Education and Services (with Martin ES and Roberts M), Daughters of Charity Health Services of Austin, $48,525, 1991-92.

Double-blind Evaluation of Alpidem, Buspirone and Placebo in Patients with Generalized

Anxiety Disorder (with Sack M and ADC Center for Clinical Research), Searle Pharmaceuticals, 1991-92.

Cerebrospinal Fluid Metabolites and Glucose Metabolism in Post-Traumatic Aggression (with

Stanislav SW, Michals M, Linnoila M and Childs A), University Research Institute, $2,500, 1992.

Double-blind, Placebo Controlled Trial of Zatosetron in the Treatment of Generalized Anxiety

Disorder (with Thorstad W and ADC Center for Clinical Research), Lilly Research Laboratories, 1992.

Multi-center, Double-blind, Parallel Group Safety, Tolerance and Efficacy Comparison of

Placebo and HP 029 (velnacrine) in Outpatients with Alzheimer's Disease (with Little J and ADC Center for Clinical Research), Hoechst-Roussel Pharmaceuticals, 1991-93.

A Prospective, Multicenter, Open-label Study of the Safety of Abecarnil in Outpatients with

Generalized Anxiety Disorder (with Sack M and ADC Center for Clinical Research), Sandoz Pharmaceuticals, 1991-93.

A Double-blind, Placebo-controlled, Multicenter Study of Fixed Doses of Paroxetine (10 mg, 20

mg & 40 mg) Given as a Single Oral Dose Daily, in the Treatment of Panic Disorder (with Kreisle JE, and ADC Center for Clinical Research), SmithKline Beecham Pharmaceuticals, 1993.

Neuropsychiatric Clinical Pharmacology Development Grant (with Childs A, Stanley DA,

Michals ML, Stanislav S), Healthcare International, Inc., $295,000, 1987-94. Double-blind, Parallel Group Efficacy and Safety Comparison of HP 749 (besipridine) and

Placebo in Alzheimer's Disease (with Little J and ADC Center for Clinical Research), Hoechst-Roussel Pharmaceuticals, 1993-94.

Double-blind, Placebo Controlled Study of Ondansetron in the Treatment of Alzheimer's Disease

(with Little J and ADC Center for Clinical Research), Glaxo Pharmaceuticals, Inc., 1993-94.

Effects of Naltrexone on Self Abuse Episodes and Neurochemical Markers in Self Injurious

Behavior Associated with Personality Disorders of the Flamboyant Subtype (Eggert AE – fellow; Crismon -- mentor), ASHP Foundation Fellowship in Psychiatric Drug Therapy, $54,200, 1993-95.

Six Month Efficacy and Safety Study of Besipridine Hydrochloride (HP 749) in Patients with

Alzheimer's Disease. (with Little J and ADC Center for Clinical Research), Hoechst-Roussel Pharmaceuticals, 1994-95.


Page 8 August 2016

Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Three Doses of CP-118,954 for 12 Weeks to Patients with Alzheimer's Disease. (with Little J and ADC Center for Clinical Research), Pfizer Pharmaceuticals, 1994-95.

Olanzapine versus Placebo in the Treatment of Patients with Psychosis Associated with

Dementia. (with Winston J and ADC Center for Clinical Research), Lilly Research Laboratories, 1994-95.

Double-blind, Placebo Controlled, Parallel Group, BID, Dose Finding Study of Adatanserin HCl

Capsules in Outpatients with Generalized Anxiety Disorder. (with Thorstadt W and ADC Center for Clinical Research), Wyeth Ayerst Pharmaceuticals, 1994-95.

Expansion of Clinical Pharmacy Services in a State Psychiatric Institution (with Dorson PG),

Austin State Hospital, Texas Department of Mental Health and Mental Retardation, $462,511, 1983-97.

Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of Milameline

in Patients with Probable Alzheimer’s Disease. (with Little J and ADC Center for Clinical Research), Parke-Davis Pharmaceutical Research, 1995-97.

A 48 Week Double-blind, Placebo Controlled, Parallel Group, Fixed Dose Study of the Efficacy,

Safety and Cost Effectiveness of 25 µg SB 202026 BID in Patients Suffering from Dementia of the Probable Alzheimer’s Type. (with Little J and ADC Center for Clinical Research), SmithKline Beecham Pharmaceuticals, 1996-98.

Texas Medication Algorithm Project (TMAP), Phase 2: A Feasibility Study of the Use of

Medication Algorithms in Public Sector Patients with Severe and Persistent Mental Illness. (with Rush AJ [PI], Shon SP, Toprac MG, Altshuler KZ), Texas Department of Mental Health and Mental Retardation, $53,300, 1996-97.

Texas Medication Algorithm Project (TMAP), Phase 3: An Evaluation of the Clinical and

Economic Impact of Medication Algorithms in Public Sector Patients with Severe and Persistent Mental Illness. (with Rush AJ [PI], Shon SP, Toprac MG, Altshuler KZ), Meadows Foundation, $719,000, 1997-98.

A Study of the Cost of Illness of Alzheimer’s Disease. (with Shepherd MD [PI], Smeeding JE,

Jermain DM, Hicks PB), Novartis Pharmaceuticals, 1997-99. Implementation of a Clinical Pharmacy Training Program in a State Psychiatric Institution (with

Dorson PG), Austin State Hospital, Texas Department of Mental Health and Mental Retardation, $440,574, 1982-2000.

Texas Medication Algorithm Project (TMAP), Phase 3: An Evaluation of the Clinical and

Economic Impact of Medication Algorithms in Public Sector Patients with Severe and Persistent Mental Illness. (with Rush AJ [PI], Shon SP, Toprac MG, Altshuler KZ), Texas Department of Mental Health and Mental Retardation, $2,800,000, 1997-2000.


Page 9 August 2016

Texas Medication Algorithm Project (TMAP), Phase 3: An Evaluation of the Clinical and Economic Impact of Medication Algorithms in Public Sector Patients with Severe and Persistent Mental Illness. (with Rush AJ [PI], Shon SP, Toprac MG, Altshuler KZ), Robert Wood Johnson Foundation, $1,800,000, 1997-2000.

A Comparison of Practicing Psychiatrists with Academic Experts in Treating Psychiatric

Disorders in Individuals with Mental Retardation. (with Patel N), Pfizer Pharmaceuticals, 1999-2000.

Psychopharmacy Research Fellowship Training Grant. (Baumgartner J – fellow; Crismon --

mentor), American College of Clinical Pharmacy Research Institute, $22,500, 1999-2000. Mental Health Outcomes Research Grant (with Rush AJ, Trivedi MH, Shon SP), Forest

Laboratories, 1999-2000. Fixed Dose Comparison of the Safety and Efficacy of Lu 26-054, Citalopram, and Placebo in the

Treatment of Major Depressive Disorder. (with Hemlock C, and Radiant Research - Austin), Forest Laboratories, 1999-2000.

A Descriptive Analysis of Risperidone and Olanzapine use within the Texas Medicaid Program:

Utilization and Costs. (with Johnsrud MT), Janssen Research Institute, 1999-2000. Placebo-Controlled Evaluation of the Safety and Efficacy of Lu 26-054 in the Prevention of

Depression Relapse. (with Hemlock C, and Radiant Research - Austin), Forest Laboratories, 1999-2001.

Children’s Medication Algorithm Project, Phase II: A Feasibility Trial. (with Hughes C, Toprac

MG, Emslie G, Pliszka S, Sedillo A), Houston Endowment, $100,000, 1999-2001 Children’s Medication Algorithm Project, Phase II: A Feasibility Trial. (with Hughes C, Toprac

MG, Emslie G, Pliszka S, Sedillo A), Hogg Foundation, $85,100, 1999-2001 Evaluating Adherence with Medication Algorithms, Information Research Award, USP

Fellowship Program (Bettinger T – fellow; Crismon -- mentor), United States Pharmacopoeia, $15,000, 2000-2001.

Flexible Dose Comparison of the Safety and Efficacy of LU 26-054 and Placebo in the

Treatment of Generalized Anxiety Disorder. (with Hemlock C, and Radiant Research - Austin), Forest Laboratories, 2000-2001.

A Descriptive Analysis of Utilization and Expenditure Trends for Selective Serotonin Reuptake

Inhibitors (SSRIs) within the Texas Medicaid Program: Utilization and Costs. (with Johnsrud MT), Forest Laboratories, Inc., 2000-2001.

A Retrospective Analysis of Citalopram Use in Children and Adolescents. (with Baumgartner J

and Emslie G), Forest Laboratories, 2000-2001.


Page 10 August 2016

Evaluation of the Safety and Efficacy of Lu 26-054 in the Prevention of Depression Recurrence. (with Hemlock C, and Radiant Research - Austin), Forest Laboratories, 2000-2003.

An Analysis of Schizophrenia Treatment Patterns Before and After Implementation of a

Managed Mental Health Pilot Program in Texas. (with Johnsrud MT), Janssen Pharmaceutica, 2001.

Proposal to Provide Technical Assistance to States for the Implementation of Medication

Algorithms for the Treatment of Schizophrenia and Major Depressive Disorder. (with Shon SP [PI], Canales PL, Miller AL, Trivedi MH), Substance Abuse and Mental Health Services Administration, $98,193, 2000-2002.

Children’s Medication Algorithm Project, Phase II: A Feasibility Trial. (with Hughes C, Toprac

MG, Emslie G, Pliszka S, Sedillo A), Meadows Foundation, $647,964, 1999-2002.

One-year Rehospitalization Rates of Bipolar Patients Discharged on a Mood Stabilizer Alone versus a Mood Stabilizer plus an Atypical Antipsychotic. (with Patel NC), Eli Lilly and Company, 2002-2003.

Incidence of extrapyramidal side effects associated with the initiation of selected atypical

antipsychotic agents within a population of Texas Medicaid patients. (with Johnsrud M), AstraZeneca Pharmaceuticals, 2002-03.

Proposal to Provide Technical Assistance to States for the Implementation of Medication

Algorithms for the Treatment of Schizophrenia and Major Depressive Disorder. (with Shon SP [PI}, Miller AL), Robert Wood Johnson Foundation, $380,737, 2000-2003.

Antipsychotic use in the Texas Department of Criminal Justice (with Johnsrud M), Janssen

Pharmaceutica, 2003. TMAP Data Analyses. (with Rush AJ [PI]). University of Texas Southwestern Medical Center

(subcontract from Robert Wood Johnson Foundation), $55,228, 2001-2003.

Effectiveness of a Patient and Family Education Program for Children with Depression or ADHD. (with Toprac M, Lopez M), Forest Laboratories, 2002-2004.

An Evaluation of Antipsychotic Use in Children Treated within Four State Medicaid Systems.

(with Patel NC), Eli Lilly and Company, 2003-04. Pilot project to provide technical assistance for best practices in mental health. (with Shon SP

[PI]), Substance Abuse and Mental Health Services Administration, $249,911, 2002-2004.

Antipsychotic Use in Children and Adolescents: Research Fellowship Award (Patel NC – fellow; Crismon ML – mentor), National Institute of Mental Health (1 F32 MH068042-01), $73,875, 2003-2004.

Unrestricted Support of Graduate Education in Mental Health Outcomes, Janssen

Pharmaceutica, 2004-05.


Page 11 August 2016

Antipsychotic Polypharmacy: An Examination of Utilization, Predictors, and Effectiveness.

(with De Leon, A), AstraZeneca Pharmaceuticals, 2004-2005. Implementation of TMAP algorithms, (with Shon SP), University of Hawaii, Hawaii Department

of Mental Health, $10,000, 2005.

Implementation of TMAP algorithms, (with Shon SP), Barriere County Mental Health Authority, St. Joseph, MI, $10,000, 2006.

Implementation of TMAP algorithms, (with Shon SP), Jackson Evidence Based Partnership, Jackson, MI, $10,000, 2006.

A Markov Modeling Study of Vagal Nerve Stimulation in Treatment Resistant Depression

(with Novak S, Bettinger T), Cyberonics, Inc, 2006-07. Clinical Psychopharmacology Education and Clinical Services, (with Bettinger T, Argo T),

Austin Medical Education Program, Seton Health Network, $100,000, 2004-08.

Evaluation of a Medicaid Value Added Program for Implementation of the Texas Implementation of Medication Algorithms in MHMRA of Harris County (with Johnsrud M & Argo T), MHMRA of Harris County (subcontract of Texas Medicaid approved value added program with contract from Bristol Myers Squibb), $160,000, 2005-2008.

Implementation and Evaluation of Best Practices in Public Mental Health. (with Argo T), Texas

Department of State Health Services (formerly TDMHMR), $1,788,084, 2000-2008; (total award for 2007-08 is $519,665).

Development, Implementation, and Evaluation of a Web-Based Interactive Learning Program

(Web TMAP) for Pharmacotherapy Best Practices for Common Mental Disorders Treated by Medicaid Providers (with Johnsrud M, Argo T, Jensen P), Texas Medicaid approved value added program with contract from Eli Lilly and Company, 2005-2010, $508,000.

Grants and Contracts Received as Co-Investigator:

Desipramine Plasma Concentrations and Clinical Response (with Ereshefsky L [PI] and Warren JA), Merrell National Pharmaceuticals, 1981.

Intravenous Infusion Studies (with Sagraves R [PI]), IVAC Laboratories, 1982. Comparative Bioavailability of Furosemide from Solution and 40 mg Tablets with Different

Dissolution Characteristics Following Oral Administration in Normal Men (with Doluisio JT, Smith RV, Trickett PC and Waller ES [PI]), Hoechst Pharmaceuticals, 1982-83.

Effects on Manic-Depressive Subjects of Participation in Biofeedback Relaxation Training

and/or Participation in a Semi-structured Didactic Psychotherapy (with Crockett MS [PI]), University Research Institute, $5,400, 1982-83.


Page 12 August 2016

Bioavailability Study of the Old versus New Tablet Formulations of Chlorprothixene in

Schizophrenic Patients (with Ereshefsky L [PI]), Hoffman LaRoche, Inc., 1987. Chronic Therapy of Hypertension in Renal Insufficiency: Effects of Dilevalol or Atenolol on

Renal Function (with Godley PJ [PI], Stevens TW, Moore ES, Karboski JA), Pharmacodynamics Research Incorporated, 1988.

Fluoxetine vs. Placebo in Geriatric Patients with Major Depressive Disorder (with Winston J [PI]

and ADC Center for Clinical Research), Lilly Research Laboratories, 1991. Pharmacokinetics of Risperidone in Geriatric Patients, Renal Insufficiency Patients, and Hepatic

Insufficiency Patients as Compared with Healthy Normal Adults (with Horton M, Sack M [PI], and ADC Center for Clinical Research), Janssen Research Foundation, 1992.

Pharmacokinetics of Multiple Oral Doses of HP 029 (Velnacrine) in Normal Subjects and

Patients with various Degrees of Renal Insufficiency (with Simpson K, Horton M, Sack, M [PI], and ADC Center for Clinical Research), Hoechst-Roussel Pharmaceuticals, Inc., 1992.

A Phase II, 28-day, Multicenter, Randomized, Double-blind, Comparative, and Placebo-

controlled, Parallel-group Safety, Tolerance, and Efficacy Study of 5, 10, and 20 mg of CL 284,846, Compared with 10 mg of Zolpidem or Placebo, in Adult Out-patients with Insomnia. (with Kreisle JE [PI] and ADC Center for Clinical Research), Lederle Pharmaceuticals, 1994-95.

The Effect of Psychiatric Pharmacy Services on Patient Outcomes. (with Dorson PG [PI] and

Canales PL), TSHP R&E Foundation, $2,500, 1996-97. Fluoxetine Plus Pindolol Versus Fluoxetine Plus Placebo in the Treatment of Major Depression.

(with Hemlock C [PI] and Texas Research Associates), Lilly Research Laboratories, 1996-97.

A Placebo Controlled Study of the Efficacy and Safety of a Topical Patch Formulation of

Xanomeline in Alzheimer’s Disease. (with Little J [PI] and ADC Center for Clinical Research), Lilly Research Laboratories, 1996-97.

The Effects of Pharmaceutical Care on Clinical Outcomes in an Inpatient Psychiatric Setting.

(with Dorson PG [PI] and Canales PL), ASHP Foundation, $6,000, 1996-98. Establishment of a Psychiatric Pharmacy Center for Community Mental Health: A Pilot Study.

(with Nwangu VU [PI], Ingham D, Stakem R, Gansert L), ASHP Foundation, $6,000, 1997-98.

Children’s Medication Algorithm Project, Phase 1; Consensus Conference for Development of

ADHD Algorithms. (with Toprac MG [PI], Hughes C, Pliszka S, Lopez M), Hogg Foundation, $21,755, 1998.


Page 13 August 2016

Children’s Medication Algorithm Project, Phase 1; Consensus Conference for Development of MDD Algorithms. (with Toprac MG [PI], Hughes C, Emslie G, Lopez M), Meadows Foundation, $23,655, 1998.

A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-

release Capsules and Paroxetine in Outpatients with Generalized Social Anxiety Disorder (with Hemlock C [PI] and Radiant Research), Wyeth-Ayerst Research, 2000-2001.

Olanzapine versus Risperidone in the Treatment of Schizophrenia: A Comparison of

Prescription Drug and Health Care Service Utilization and Costs. (with Rascati KL [PI], Johnsrud MT), Eli Lilly and Company, 2000-2001.

Effectiveness of a Patient and Family Education Program for Children with Depression or

ADHD. (with Toprac M [PI], Lopez M),Eli Lilly and Company, 2002-2003. Comorbidity Algorithms Project (COMAP). (with Shon SP [PI], Arredondo R), National

Institute on Drug Abuse, $38,280, 2002-2003. Atypical Use and Diagnoses in Texas Medicaid Patients. (with Rascati KL [PI], Johnsrud

MT), Bristol-Myers Squibb, 2002-2003.

A Comprehensive Descriptive Analysis of Quetiapine Utilization Patterns within the Texas Medicaid Program. (with Johnsrud MT [PI]), AstraZeneca, 2003-04.

Center for Education and Research on Mental Health Therapeutics (CERT), (with Crystal S [PI

– Rutgers University]; Jensen P & Olfson M [Co-I – Columbia University]), Agency for Healthcare Research and Quality, $4,000,000, 2006-10.

A Comprehensive Description Analysis of ADHD Medication Treatment Patterns within the

Texas Medicaid Program. (with Johnsrud MT [PI]), Shire Development Inc, 2008-09.

PUBLICATIONS Refereed Articles

1) Young RS, Grzyb SE, Crismon ML. Recurrent cerebellar dysfunction as related to chronic gasoline sniffing in an adolescent girl. Clinical Pediatrics 1977;16:706-08.

2) Crismon ML. Drug induced extrapyramidal symptoms. U S Pharmacist 1982;7(1):33-42. 3) *Warren JA, Crismon ML. Carbamazepine in the treatment of manic-depressive illness.

Clinical Pharmacy 1982;1:266-68. 4) Saklad SR, Ereshefsky L, Jann MW, Crismon ML. Clinical pharmacists impact on

prescribing in an acute adult psychiatric facility. Drug Intell Clin Pharm 1984;18:632-34.


Page 14 August 2016

5) Kastenholz KV, Crismon ML. Buspirone, a novel nonbenzodiazepine anxiolytic. Clinical Pharmacy 1984;3:600-07.

6) Fabre LF, Crismon ML. Efficacy of fluoxetine in outpatients with major depression.

Current Therapeutic Research 1985;37:115-23. 7) *Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin specific second

generation antidepressant. Pharmacotherapy 1987;7:1-14. 8) Waller ES, Crismon ML, Smith RV, Bauza MT, Doluisio JT. Comparative bioavailability

of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. Biopharm Drug Disposition 1988;9:211-18.

9) *Wells AJ, *Sommi RW, Crismon ML. Neuroleptic rechallenge after NMS: Case report

and literature review. Drug Intell Clin Pharm 1988;22:475-79. 10) Childs A, Crismon ML. The use of cranial electrotherapy stimulation in post-traumatic

amnesia. Brain Injury 1988;2:243-47. 11) *Dorson PG, Crismon ML. Chlorpromazine accumulation and sudden death in a patient

with renal insufficiency. Drug Intell Clin Pharm 1988;10:776-78. 12) Crismon ML, Childs A, Wilcox RE, Barrow N. Effect of bromocriptine on speech

dysfunction in patients with diffuse brain injury ("Akinetic Mutism"). Clinical Neuropharmacology 1988;11:462-66.

13) *Greer M, Kirk KW, Crismon ML. Development and pilot testing of a community

practice clinical pharmacy decision making instrument. Evaluation & Health Professions 1989;12:207-31.

14) Crismon ML, Dorson PG. Comment: chlorpromazine sudden death. DICP Ann

Pharmacother 1989;23:512-13. 15) Choc MG, Hsuan F, Honigfeld, G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR,

Hirschowitz J, Wagner R. Single vs. multiple dose pharmacokinetics of clozapine in psychiatric patients. Pharmaceutical Research 1990;7:347-51.

16) Crismon ML, *Jermain DM. Clozapine for refractory schizophrenia. Hospital Therapy

1990;15:705-06, 708-10. 17) Crismon ML, *Jermain DM, *Torian SJ. Attitudes of pharmacy students toward mental

illness. Am J Hosp Pharm 1990;47:1369-73. 18) *Jermain DM, Crismon ML. Pharmacotherapy of obsessive-compulsive disorder.

Pharmacotherapy 1990;10:175-98. 19) Crismon ML. Psychotropic drugs in the elderly: Principles of use. American Pharmacy

1990;NS30(12):57-63.


Page 15 August 2016

20) *Michals M, *Stanley DA, Crismon ML, Barrow NE. Elevated tricyclic antidepressant

plasma concentrations associated with fluoxetine: two case reports. Jour Neuropsychiatry and Clin Neurosciences 1990;2:466-67.

21) *Jermain DM, Crismon ML. Students' attitudes toward the mentally ill before and after

clinical rotations. Am Jour Pharm Education 1991;55:45-48. 22) *Jermain DM, Crismon ML, Martin ES. Population pharmacokinetics of lithium.

Clinical Pharmacy 1991;10:376-81. 23) Martin ES, Crismon ML, Godley PJ. Post-induction carbamazepine clearance in an adult

psychiatric population. Pharmacotherapy 1991;11:296-302. 24) *Volf N, Crismon ML. Leukemia in patients with bipolar mood disorder: Is lithium

contraindicated? DICP Ann Pharmacother 1991;25:948-51. 25) *Eggert AE, Crismon ML. Dealing with insomnia. The evaluation and treatment of sleep

disorders. American Druggist 1992;205(5):83,87-88,91,93,95-96,98. 26) Jermain DM, Crismon ML, Nisbet RB. Controversies over the use of magnesium sulfate

in delirium tremens. Ann Pharmacother 1992;26:650-02. 27) Jermain DM, Crismon ML. Psychotropic drug-related rhabdomyolysis. Ann

Pharmacother 1992;26:948-54. 28) *Richer M, Crismon ML. Pharmacological management of the sexual offender. Ann

Pharmacother 1993;27:316-20. 29) *Michals ML, Crismon ML, Misko JS, Childs A. A double-blind, sham-controlled

evaluation of cranial electrotherapy stimulation in posttraumatic memory impairment. J Head Trauma Rehabil 1993;8(4):77-86.

30) Michals ML, Crismon ML, *Roberts S, Childs A. Clozapine response and adverse effects

in nine brain-injured patients. J Clin Psychopharmacol 1993;13:198-203. 31) Stanislav SW, *Barker K, Crismon ML, Childs A. Outcome assessment of a clinical

psychopharmacy consultation service in a private psychiatric institution. Am J Hosp Pharm 1994;51:778-781.

32) Stanislav SW, *Fabre T, Crismon ML, Childs A. Buspirone's efficacy in organic-induced

aggression. J Clin Psychopharmacol 1994;14:126-130. 33) Crismon ML. Tacrine: First drug approved for Alzheimer's disease. Ann Pharmacother

1994;28:744-751. 34) *Eggert AE, Crismon ML, Dorson PG. Lack of effect of fluoxetine on clozapine plasma

concentrations. J Clin Psychiatry 1994;55:454-455.


Page 16 August 2016

35) *Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine rechallenge after marked

liver enzyme elevation. J Clin Psychopharmacol 1994;14:425-426. 36) *Garcia G, Dorson PG, Crismon ML. Seizures in two patients after the addition of

lithium to a clozapine regimen. J Clin Psychopharmacol 1994;14:426-428. 37) *Cyr M, Dorson PG, Crismon ML. Changes in effectiveness of psychotherapeutic drug

level monitoring program after lessening pharmacy involvement. Hospital Pharmacy 1995;30:116, 118-119.

38) Antuono PG, Mentane Study Group. Effectiveness and safety of velnacrine for the

treatment of Alzheimer’s disease. Arch Intern Med 1995;155:1766-72. 39) *Canales PL, Crismon ML. The one minute counselor: a pharmacist’s guide to transient

insomnia. Jour Am Pharm Assoc 1996;NS36:421-22. reprinted in ACCP Report 1996;15(9):7-8.

40) Huff FJ, Antuono PG, Delagandara JE, McDonald MA, Cutler NR, Cohen SR, Green RC,

Zemlan FP, Crismon ML, Alter M, Shipley JE, Reichman WE. A treatment and withdrawal trial of besipridine in Alzheimer's disease. Alzheimer’s Disease and Assoc Disorders 1996;10:93-102.

41) Gidal BE, Wagner ML, Privitera MD, Dalmady-Israel C, Crismon ML, Fagan SC, Graves

NM. Current developments in neurology, part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. Ann Pharmacother 1996;30:1272-76.

42) Gidal BE, Crismon ML, Wagner ML, Fagan SC, Privitera MD, Dalmady-Israel C, Graves

NM. Current developments in neurology, part II. Advances in the pharmacotherapy of Alzheimer disease, Parkinson’s disease, and stroke. Ann Pharmacother 1996;30:1446-51.

43) *Pabis DJ, Dorson PG, Crismon ML. Evaluation of inpatient depot antipsychotic

prescribing. Ann Pharmacother 1996;30:1381-86. 44) *Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with

treatment-resistant schizophrenia from clozapine to risperidone. Psychiatric Services 1996;47:1382-84.

45) Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP, Paroxetine Panic Study

Group. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am Jour Psychiatry 1998;155:36-42.

46) Crismon ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors

administered in Alzheimer’s disease. Pharmacotherapy 1998;18(2 Pt 2):47S-54S. 47) Khachaturian ZS, Cummings JL, Crismon ML, Jann M, Meek PD, Beck C. New advances

in the treatment of Alzheimer’s disease. Pharmacotherapy 1998;18(2 Pt 2):79S-82S.


Page 17 August 2016

48) Stanislav SW, Crismon ML, Childs NL. Cerebrospinal fluid monoamine metabolites and glucose metabolism in post-traumatic aggression. Biological Psychiatry 1998;43:619-21.

49) Crismon ML, Fankhauser MP, Hinkle GH, Jann MW, Juni H, Love RC, Ray MD,

Stimmel GL, Wells BG. Psychiatric pharmacy practice specialty certification process. Am J Health-Syst Pharm 1998;55:1594-98.

50) Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ.

Texas Medication Algorithm Project: Definitions, rationale and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-51.

51) Chiles JA, Miller AL, Crismon ML, Rush AJ, Krasnoff AS, Shon S. The Texas

Medication Algorithm Project. Development and implementation of the schizophrenia algorithm. Psychiatric Services 1999;50:69-74.

52) Shon SP, Toprac MG, Crismon ML, Rush AJ. Strategies for implementing psychiatric

medication algorithms in the public sector. Jour Practical Psychiatry & Behavioral Health 1999;5:32-36.

53) Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RMA, Kahn DA, DeBattista C,

Nelson JC, Nierenberg AA, Sackeim HA, Thase ME, and the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60:142-156.

54) *Conner TM, Crismon ML, *Still DJ. A critical review of selected economic analyses of

pharmacotherapy for depression. Annals Pharmacother 1999;33:364-372 55) Rush AJ, Crismon ML, Toprac MG, Shon SP, Rago WV, Miller AL, Suppes T, Trivedi

MH, Biggs MM, Shores-Wilson K, Kashner TM, Altshuler KZ. Implementing guidelines and systems of care: Experiences with the Texas Medication Algorithm Project (TMAP). Jour Practical Psychiatry & Behavioral Health 1999;5:75-86.

56) Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi

MH, Swann A, Biggs MM, Shores-Wilson K, Kashner M, Pigott TA, Chiles CA, Gilbert DA, Altshuler KZ. Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project. J Clin Psychiatry 1999;60:284-291.

57) *Lee JW, Crismon ML, Dorson PG. Seizure associated with olanzapine use. Annals

Pharmacother 1999;33:554-556. 58) *Llana ME, Crismon ML. Methylphenidate: Increased abuse or appropriate use. Jour

Am Pharm Assoc 1999;39:526-530. 59) Hamelin BA, Dorson PG, *Pabis D, *Still DJ, Bouchard RH, Pourcher E, Rail J, Turgeon

J, Crismon ML. CYP2DG mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy 1999;19:1057-1063.


Page 18 August 2016

60) *Canales PL, Olsen J, Miller AL, Crismon ML. The role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999;12:179-188.

61) Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The TMAP

schizophrenia algorithms. J Clin Psychiatry 1999;60:649-657. 62) Hughes CW, Emslie GJ, Crismon ML, Wagner KD, Birmaher B, Geller B, Pliszka S,

Ryan N, Stober M, Trivedi MH, Toprac MG, Sedillo A, *Llana ME, Lopez M, Rush AJ, and the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. The Texas Childhood Medication Algorithm Project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1442-1454.

63) *Defilippi JL, Crismon ML. The use of antipsychotic agents in patients with dementia.

Pharmacotherapy 2000; 20:23-33. 64) Pliszka SR, Greenhill LM., Crismon ML, Sedillo A, Carlson C, Conners MK, McCracken

JT, Swanson JM, Hughes CW, Llana M, Lopez M, Toprac, M, and the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention Deficit Hyperactivity Disorder, Part II. J Am Acad Child Adolesc Psychiatry 2000;39:908-919.

65) Pliszka SR, Greenhill LM., Crismon ML, Sedillo A, Carlson C, Conners MK, McCracken

JT, Swanson JM, Hughes CW, Llana M, Lopez M, Toprac, M, and the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention Deficit Hyperactivity Disorder, Part II: Tactics. J Am Acad Child Adolesc Psychiatry 2000;39:920-927.

66) *Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine induced glucose

dysregulation. Annals Pharmacother 2000;34:865-867. 67) *Richards KM, Shepherd MD, Crismon ML, Snyder EH, Jermain DM. Medical services

utilization and charge comparisons between elderly patients with and without Alzheimer’s disease in a managed care organization. Clinical Therapeutics 2000;22:775-791.

68) Toprac MG, Rush AJ, *Conner TM, Crismon ML, Dees M, Hopkins C, Rowe V, Shon

SP. The Texas Medication Algorithm Project patient and family education program: a consumer-guided initiative. J Clin Psychiatry 2000;61:477-486.

69) Biggs MM, Shores-Wilson K, Rush AJ, Carmody TJ, Trivedi MH, Crismon ML, Toprac

MG, Mason M. A comparison of alternative assessments of depressive symptom severity: a pilot study. Psychiatry Research 2000;96:269-279.


Page 19 August 2016

70) *Wright R, Crismon ML. Comparison of three a priori methods and one empirical method in predicting lithium dosage requirements. Am J Health-Syst Pharm 2000;57:1698-1702.

71) Mellman TA, Miller AL, Weissman E, Crismon ML, Essock SM, Marder SR. Evidence

based medication treatment for severe mental illness: a focus on guidelines and algorithms. Psychiatric Services 2001;52:619-625.

72) Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M, Crismon ML, Toprac

MG, Rush AJ, Shon SP, Altshuler KZ. Texas Medication Algorithm Project – development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry 2001;62:439-447.

73) *Canales PL, Dorson PG, Crismon ML. Outcomes assessment of clinical pharmacy

services in a psychiatric inpatient setting. Am J Health-Syst Pharm 2001;58:1309-1316. 74) *Patel NC, Crismon ML, Rush AJ, Frances A. Practitioner versus medication-expert

opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders. Am J Hlth-Syst Pharm 2001;57:1824-9.

75) Shores-Wilson K, Biggs MM, Miller AL, Carmody TJ, Chiles JA, Rush AJ, Crismon ML,

Toprac MG, Witte BP, Webster JC. Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. Int J Methods Psychiatric Research 2002;11:45-53.

76) Suppes T, Dennehy EB, Swann AC, Bowden C, Calabrese J, Hirschfeld R, Keck PE, Sachs

G, Crismon ML, Toprac M, and Shon SP. Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000. J Clin Psychiatry 2002;63:288-299.

77) *Patel NC, Sierk P. Dorson PG, Crismon ML. Experience with ziprasidone. J Am Acad

Child Adolesc Psychiatry 2002;41:495. 78) *Patel NC, Dorson PG, *Edwards N, Mendelson S, Crismon ML. One-year

rehospitalization rates of patients discharged on atypical versus traditional antipsychotics. Psychiatric Services 2002;53:891-893

79) *Patel NC, *Yeh JY, Shepherd MD, Crismon ML. Secretin treatment for autism: a

critical analysis. Pharmacotherapy 2002;22:905-14. 80) *Patel NC, *Sanchez RJ, Johnsrud MT, Crismon ML. Trends in antipsychotic use in a

Texas Medicaid population of children and adolescents: 1996 to 2000. Jour Child Adolescent Psychopharmacol 2002;12:219-227.

81) *Baumgartner JL, Emslie GJ, Crismon ML. Citalopram in children and adolescents with

depression or anxiety. Annals Pharmacother 2002;36:1692-97.


Page 20 August 2016

82) Johnsrud MT, Crismon ML. Economic evaluation of citalopram use and expenditures among recipients in the Texas Medicaid Program. J Managed Care Pharm 2002;8:396-402.

83) Schur SB, Sikich L, Findling RL; Malone RP, Crismon ML, Derivan, A, MacIntyre II

JC, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS. Treatments for aggression in children and adolescents: a review. J Am Acad Child Adolesc Psychiatry 2003;42:132-44.

84) Pappadopulos E, MacIntyre JC, Crismon ML, Findling RL, Malone RP, Derivan A,

Schooler N, Sikich L, Greenhill L, Schur SB, Felton C, Kanzler H, Rube D, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS. Treatment recommendations for the use of antipsychotics for aggressive Youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry 2003;42:145-61.

85) *Cala S, Crismon ML, *Baumgartner JL. A survey of herbal medicines in children with

ADHD or depressive disorders. Pharmacotherapy 2003;23:222-30. 86) Pliszka SR, Lopez M, Crismon ML, Toprac M, Hughes CW, Emslie GJ, Boemer C. A

feasibility study of the Children’s Medication Algorithm Project (CMAP) algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:279-87.

87) Kashner TM, Carmody TJ, Suppes T, Rush AJ, Crismon ML, Miller AL, Toprac M,

Trivedi M. Catching-up on health outcomes: The Texas Medication Algorithm Project. Health Serv Res 2003;38:311-31.

88) Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, Witte B, Shon SP, Rago WV, Altshuler KZ. Texas Medication Algorithm Project – Phase III (TMAP-III): rationale and design. J Clin Psychiatry 2003;64:357-69.

89) Suppes T, Dennehy E, Rush AJ, Crismon ML, Kashner, TM, Carmody TJ, Toprac MG, Biggs MM, Shores-Wilson K, Witte B, Trivedi MH, Steven SP. Texas Medication Algorithm Project: clinical results for patients with a history of mania. J Clin Psychiatry 2003;64:370-82.

90) Crismon ML, *DeLeon A, Miller AL. Aripiprazole: Does partial dopaminergic agonism translate into clinical benefits? Annals Pharmacother 2003;37:738-40.

91) Defilippi J, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs & Aging 2003;20:437-44.

92) Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus

risperidone in the treatment of schizophrenia: A comparison of costs among Texas Medicaid patients. Pharmacoeconomics 2003;21:683-97.

93) *Chuang WC, Crismon ML. Evaluation of a schizophrenia medication algorithm in a

state hospital. Am J Hlth-Syst Pharm 2003;60:1459-67.


Page 21 August 2016

94) *Hartnell NR, Wilson JP, *Patel NC, Crismon ML. Patterns associated with selective

serotonin reuptake inhibitor spontaneous adverse event reporting. Annals Pharmacother 2003;37:1387-91.

95) Baker CB, Johnsrud MT, Crismon ML, Rosenheck RM, Woods SW. Quantitative

analysis of sponsorship bias in economic studies of antidepressants. Brit Jour Psychiatry 2003;183:498-506.

96) Dewan NA, Conley D, Svendsen D, Shon SP, Staup JR, Miller AL, Crismon ML, Rush

AJ, Trivedi M, Skale T, Keck PE, Strawkowski SM. A quality improvement process for implementing the Texas Algorithm for schizophrenia in Ohio. Psychiatric Services 2003;54:1646-49.

97) Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental

health: a systematic review. Pharmacotherapy 2003;23:1634-44. 98) Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML,

Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine 2004;34:73-82.

99) Dennehy EB, Suppes T, Rush AJ, Crismon ML, Witte B, Webster J. Development of a

computerized assessment of clinician adherence to a treatment guideline for patients with bipolar disorder. Jour Psych Research 2004;38:285-94.

100) Emslie GJ, Hughes CW, Crismon ML, Lopez M, Pliszka S, Toprac MG, Boemer C. A

feasibility study of the childhood depression medication algorithm: the Texas Children’s Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004;43:519-27.

101) Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles J, Conley RR, Crismon ML,

Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller D, McEvoy J, Rush AJ, Saeed SA, Schooler NR, Shon S, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 Update. J Clin Psychiatry 2004;65:500-8.

102) *Bettinger TL, Crismon ML, Trivedi MH, Grannemann B, Shon SP. Clinician

adherence to an algorithm for depression in the Texas public mental health sector. Psychiatric Services 2004;55:703-5.

103) *De Leon A, *Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its

pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics 2004;26:649-66.


Page 22 August 2016

104) Rush AJ, Trivedi M, Carmody TJ, Biggs MM, Shores-Wilson K, Ibrahim H, Crismon ML. One year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biological Psychiatry 2004;56:46-53.

105) Trivedi MH, Rush AJ, Crismon ML, Kashner, TM, Toprac MG, Carmody TJ, Key T,

Biggs MM, Shores-Wilson K, Witte B, Suppes, Miller AL, Steven SP. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project:. Arch Gen Psychiatry 2004;61:669-80.

106) *Patel NC, *Kistler JL, *James EB, Crismon ML. A retrospective analysis of

olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004;24:824-30.

107) Dennehy EB, Suppes T, Crismon ML, Toprac M, Carmody TJ, Rush AJ. Development

of the Brief Bipolar Disorder Symptom Scale for patients with bipolar disorder. Psychiatry Research 2004;127:137-45.

108) Velligan DI, DiCocco M, Bow-Thomas C, Cadle C, Glahn DC, Miller AL, Biggs MM,

Shores-Wilson K, McKenzie CA, Crismon ML. A brief cognitive assessment (BCA) for use with schizophrenia patients in a community clinic. Schizophrenia Research 2004;71:273-83.

109) Miller AL, Crismon ML, Rush AJ, Chiles J, Kashner M, Toprac M, Carmody T, Biggs

M, Shores-Wilson K, Chiles J, Witte B, Bow-Thomas C, Velligan DI, Trivedi M, Suppes T, Shon S. The Texas Medication Algorithm Project: clinical results for schizophrenia. Schizophrenia Bulletin 2004;30:627-47.

110) Lopez MA, Toprac MG, Crismon ML, Boemer C, *Baumgartner J, Peyson R, Sheldon

S. A psychoeducational program for children with ADHD or depression and their families: results from the CMAP feasibility study. Community Mental Health Journal 2005;41:51-66.

111) *Patel NC, Crismon ML, Hoagwood K, Jensen PS. Unanswered questions regarding

antipsychotic use in aggressive children and adolescents. Jour Child & Adolesc Psychopharm 2005;15:270-284.

112) *Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, Jensen

PS. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44:548-556.

113) *Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of

adherence measures with different psychostimulants among children and adolescents. Pharmacotherapy 2005;25:909-917.

114) Velligan DI, Prihoda TJ, Dennehy EB, Biggs MM, Shores-Wilson K, Crismon ML,

Rush AJ, Miller AL, Suppes T, Trivedi M, Kashner TM, Witte BS, Toprac M, Carmody T, Chiles J, Shon S. The Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure? Psychiatry Research 2005;135:217-228.


Page 23 August 2016

115) Suppes T, Dennehy E, Hirschfeld RMA, Altshuler LL, Bowden CL, Calíbrese CR,

Crismon ML, Ketter T, Sachs G, Swann AC. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-886.

116) *Patel NC, Crismon ML, Miller AL Johnsrud MT. Drug adherence: Effects of

decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 2005;25:1242-1247.

117) *Hunziker ME, *Suehs BT, Bettinger T, Crismon ML. Duloxetine: A new dual-acting

antidepressant medication for the treatment of major depressive disorder. Clinical Therapeutics 2005;27:1126-1143.

118) Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, Crismon ML, Carmody TJ,

Kashner TM. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychological Medicine 2005;29:1-12.

119) Johnsrud M, Crismon ML, Thompson A, Grogg A. An economic comparison of

risperidone and olanzapine use within an integrated managed mental health program. Admin Policy in Mental Health & Mental Health Services Research 2006;33:237-43.

120) *Patel NC, Crismon ML, *Pondrom M. Rehospitalization rates of patients with bipolar

disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res 2005;32:438-445.

121) *Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP.

Physician specialty associated with antipsychotic prescribing for youths in the Texas Medicaid program. Medical Care 2006;44:87-90.

122) *Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among

youths in a public mental system. Annals of Pharmacother 2006;40:205-211.

123) *Patel NC, Crismon ML, Shafer A, *DeLeon A, Lopez M, *Lane DC. Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. Social Psychiatry and Psychiatric Epidemiology 2006;40:1-6.

124) Kashner TK, Rush AJ, Crismon ML, Toprac M, Carmody TJ, Kashner TM, Miller AL,

Trivedi M, Wicker A, Suppes T. An empirical analysis of cost outcomes in the Texas medication algorithm project. Psychiatric Services 2006;57:648-59.

125) Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PT, McCracken

JT, Swanson JM, Lopez M, and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit/Hyperactivity Disorder. The Texas Children’s Medication Algorithm Project: A revision of the algorithm for the pharmacotherapy of childhood Attention Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-57.


Page 24 August 2016

126) *Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for

treatment of attention deficit/hyperactivity disorder. Annals Pharmacother 2006;40:1134-42.

127) Rush AJ, Carmody TJ, Ibrahim HM, Trivedi MH, Biggs MM, Shores-Wilson K,

Crismon ML, Toprac MG, Kashner TM. Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatric Services 2006;57:829-37.

128) Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, Suppes

T, Rush AJ. Implementation of the Texas Medication Algorithm Project Patient and Family Education Program. J Clin Psychiatry 2006;67:1362-1372.

129) *Gibson AP, Crismon ML, Mican LM, Fischer C. Retrospective evaluation of

aripiprazole in child and adolescent psychiatric inpatients. International Clinical Psychopharmacology 2007;22:101-105.

130) Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, Jensen P, Curry

J, Vitiello B, Lopez M, Shon SP, Pliszka S, Trivedi MH, and the Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. The Texas Children’s Medication Algorithm Project: Update from the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 2007;46:667-686.

131) Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock

SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson D, Schooler NR, Shon SP, Stroup TS, Miller AL. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68-1751-1762.

132) Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and Challenges:

Managing ADHD in a fast-paced world. J Manag Care Pharm 2007;13(9)(Suppl S-b):S2-S13.

133) *Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J,

Mascarenas CA. Antipsychotic medication utilization trends among Texas Veterans: 1997-2002. Annals Pharmacother 2008;42:1229-38.

134) Crismon ML. Argo T. The use of psychotropic medication for children in foster care.

Child Welfare 2009;88:71-100.

135) Romanelli LH, Landsverk J, Levitt JM, Leslie LK, Hurley MM, Bellonci C, Gries LT, Pecora PJ, Jensen PS, and the Best Practices for Mental Health in Child Welfare Steering Committee. Best practices for mental health in child welfare: Screening, assessment, and treatment guidelines. Child Welfare 2009;88:163-88.

136) Romanelli LH, Hoagwood KE, Kaplan SJ, Kemp SP, Hartman RL, Trupin C, Soto W,

Pecoro PJ, LaBarrie, Jensen PS, and the Best Practices for Mental Health in Child


Page 25 August 2016

Welfare Steering Committee. Best practices for mental health in child welfare: Parent support and youth empowerment guidelines. Child Welfare 2009;88:189-212.

137) Warden D, Rush AJ, Carmody TJ, Kashner TM, Biggs MM, Crismon ML, Trivedi MH.

Predictors of Attrition in Longer Term Depression Treatment: A TMAP Roadmap to Personalized Interventions. J Psychiatr Prac 2009;15:113-24.

138) Becker E, Crismon ML, Schafer A, *Hayatt J. SSRI Use and Behavioral Disruption

among Children and Adolescents at Austin State Hospital. Texas Medicine 2009;105(5):e1-5.

139) Bernstein IH, Rush AJ, , Suppes T, Trivedi MH, Woo A, Kyutoku Y, Crismon ML

Dennehy E, Carmody TJ. A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. International Journal of Methods in Psychiatric Research 2009;18:138-46.

140) Warden D, Trivedi MH, Carmody TJ, Gollan JK, Kashner TM, Lind L, Crismon ML,

Rush AJ. Anticipated benefits of care (ABC): Psychometrics and predictive value in psychiatric disorders Psychological Medicine 2010;40:955-65.

141) Lawson KA, Johnsrud M, Hodgkins P, Sasané R, Crismon ML. Utilization Patterns of Stimulants in ADHD in the Medicaid Population: a Retrospective Analysis of Data from the Texas Medicaid Program. Clinical Therapeutics 2012;34:944-56.

142) Knapp P, Chait A, Pappadopulos, E, Crystal S, Jensen PS, T-MAY Steering Committee. Treatment of maladaptive aggression in youth. CERT guidelines I. Engagement, assessment, and management. Pediatrics 2012;129:e1562-76.

143) Rosato NS, Correll CU, Pappadopulos, E, Chait A, Crystal S, Jensen PS, T-MAY Steering Committee. Treatment of maladaptive aggression in youth. CERT guidelines II. Treatments and ongoing management. Pediatrics 2012;129:e1577-86.

144) *Campbell AH, *Scalo JF, Crismon ML, Barner JC, Argo TR, Lawson KA, Miller AL. Attitudes toward medications and the relationship to outcomes in patients with schizophrenia. Clin Schizophr and Relat Psychoses 2015 July 28 [Epub ahead of print] PMID: 26218237.

( * Notes that author was a student or post-doctoral trainee.)

Book Chapters

1) Crismon ML. Benzodiazepine anxiolytics. In: Mungall DR, ed. Applied Clinical Pharmacokinetics. New York: Raven Press, 1983:285-302.

2) Crismon ML, Jann MW. Anxiety and insomnia. In: Young LY, Koda-Kimble MA, eds.

Applied therapeutics: the clinical use of drugs, 4th ed. Spokane: Applied Therapeutics, 1988:1155-88.


Page 26 August 2016

3) Crismon ML. Insomnia. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs, 5th ed. Vancouver, WA: Applied Therapeutics, 1992:55:1-17.

4) Crismon ML, Dorson PG. Schizophrenia. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC,

Posey LM, eds. Pharmacotherapy: a Pathophysiologic approach, 2nd ed. Norwalk, CT: Appleton & Lange, 1992:1020-43.

5) Crismon ML. Considerations in the geriatric population. In: The yellow road gets

longer: Social, economic and technological issues shaping clinical design in the '90s. Proceedings of the fifth annual APhA-APRS end-of-summer science symposium Washington, D.C.: American Pharmaceutical Association, 1992:17-35.

6) Crismon ML, Jermain DM. Sleep aid and stimulant products. In: Covington TR, ed.

Handbook of nonprescription drugs, 10th ed. Washington, D.C.: American Pharmaceutical Association, 1993:135-46.

7) Crismon ML, Jermain DM. Sleep aid and stimulant products. In: Covington TR, ed.

Handbook of nonprescription drugs, 11th ed. Washington, D.C.: American Pharmaceutical Association, 1996:179-92.

8) Crismon ML, Dorson PG. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke

GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 3rd ed. Norwalk, CT: Appleton & Lange, 1996:1367-94.

9) *Eggert AE, Crismon ML, Ereshefsky L. Alzheimer's disease. In: DiPiro JT, Talbert

RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 3rd ed. Norwalk, CT: Appleton & Lange, 1996:1325-44.

10) Rey JA, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM. Management of

major depression in adults. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1996:MD-i-MD-11.

11) Finley PR, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM. Bipolar

disorder: management of acute mania in adults. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1996:BDM-i-BDM-8.

12) Finley PR, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM. Bipolar

disorder: management of acute depression in adults. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1996:BDD-i-BDD-7.

13) Grimsley SR, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM.

Management of obsessive-compulsive disorder. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1997:OCD-i-OCD-7.


Page 27 August 2016

14) Grimsley SR, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM. Management of panic disorder in adults. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1997:PD-i-PD-7.

15) Bailey L, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM. Management

of schizophrenia. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1997:SCZ-i-SCZ-8.

16) Grimsley, Crismon ML, Dopheide JA, Goldstein LS, Hayes G, Levin GM. Management

of patients with generalized anxiety disorder. In: Manolakis P, ed. APhA guide to drug treatment protocols: a resource for creating and using disease specific pathways. Washington, D.C.: American Pharmaceutical Association, 1997:GAD-i-GAD-6.

17) Crismon ML, Eggert AE. Alzheimer's disease. In: DiPiro JT, Talbert RL, Yee GC,

Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 4th ed. Stamford, CT: Appleton & Lange, 1999:1065-82.


GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 4th ed. Stamford, CT: Appleton & Lange, 1999:1118-40.

19) Trivedi MH, Rush AJ, Crismon ML, O’Neal B, Toprac MG. Treatment guidelines and

algorithms. In: Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual Review of Drug Therapy 2000. Philadelphia, PA: W.B. Saunders Company, 2000;7:1-22.

20) Crismon ML, Eggert AE. Pharmacist care of patients with Alzheimer’s disease. In:

Pharmacist care: mental health. Alexandria, VA: National Institute for Pharmacist Care Outcomes, 2000:ALZ 1-29.

21) Crismon ML, Jermain DM. Insomnia. In: Allen LV, Berardi RR, DiSimone EM, Engle

JP, Popovich NG, Rosenthal WM, Tietze KJ, eds. Handbook of nonprescription drugs, 12th ed. Washington, D.C.: American Pharmaceutical Association, 2000:875-886.

22) Crismon ML, Jermain DM. Drowsiness. In: Allen LV, Berardi RR, DiSimone EM, Engle

JP, Popovich NG, Rosenthal WM, Tietze KJ, eds. Handbook of nonprescription drugs, 12th ed. Washington, D.C.: American Pharmaceutical Association, 2000:887-897.

23) Miller AL, Dassori A, Ereshefsky L, Crismon ML. Recent issues and developments in

antipsychotic use. In: Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual Review of Drug Therapy 2001. Philadelphia, PA: W.B. Saunders Company, 2001;8:209-235.


GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York, NY, McGraw Hill, 2002;1219-1242.


Page 28 August 2016

25) Defilippi JL, Crismon ML, Clark WR. Alzheimer’s disease. In: DiPiro JT, Talbert RL,

Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York, NY, McGraw Hill, 2002;1165-1182.

26) Crismon ML, Canales PL. Drowsiness. In: Berardi RR, DiSimone EM, Newton GD,

Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ. eds. Handbook of nonprescription drugs, 13th ed. Washington, D.C.: American Pharmaceutical Association, 2002:971-984.

27) Crismon ML, Canales PL. Insomnia. In: Berardi RR, DiSimone EM, Newton GD, Oszko

MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ. eds. Handbook of nonprescription drugs, 13th ed. Washington, D.C.: American Pharmaceutical Association, 2002:985-996..

28) Crismon ML, Canales PL. Insomnia. In: Berardi RR, McDermott JH, Newton GD,

Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ. eds. Handbook of nonprescription drugs, 14th ed. Washington, D.C.: American Pharmaceutical Association, 2004:1117-32.

29) Miller AL, Crismon ML, Hall CS, Baker CB. Advances in psychopharmacology and

pharmacoeconomics. In: Levin B, Petrila J, (eds.) Mental health services: a public health perspective, 2nd ed. New York: Oxford University Press, 2004:344-70.

30) Crismon ML, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke

GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 6th ed. New York, NY, McGraw Hill, 2005:1209-1233.

31) Bettinger T, Crismon ML. Lithium. In: Burton ME, Shaw LM, Schentag JJ, Evans WE.

(eds). Applied pharmacokinetic & pharmacodynamics: Principles of therapeutic drug monitoring, 4th ed. Baltimore: Lippincott Williams & Wilkins, 2006:798-812.

32) Crismon ML, Argo T, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC,

Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY, McGraw Hill, 2008:1099-1122.

33) Crismon ML. Clinical psychopharmacology: Advances and challenges from 1965 to

2006. Evolution of clinical pharmacy: 40 years in progress. Cincinnati, Harvey Whitney Books, 2009:320-321.

34) Crismon ML, Argo T, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC,

Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 8th ed. New York, NY, McGraw Hill, 2011:1147-72.

35) Crismon ML, Argo T, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 9th ed. New York, NY, McGraw Hill, 2014:1019-45.


Page 29 August 2016

36) Kattura RS, Crismon ML. Drug interactions with stimulants and other non-stimulants for ADHD. In: Jann MW, Penzak S, Cohen LJ, eds. Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents. New York, NY, Springer International Publishing, 2016:535-550.

37) Crismon ML, Kattura RS, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 10th ed. New York, NY, McGraw Hill. (in press)

Other Professional Publications

1) Crismon ML. The regionals--a membership link. JAPhA 1974;14:421. 2) Crismon ML, Evens RP. Effect of propranolol on serum glucose levels. In: Conner C,

ed. Drugdex, 8th ed. Denver: Micromedex Corp 1978. 3) Crismon ML, Evens RP. Antiarrhythmic drug prophylaxis of post-MI. In: Conner C, ed.

Drugdex, 10th ed. Denver: Micromedex Corp 1980. 4) Crismon ML, Evens RP. Metrizamide side effects. In: Conner C, ed. Drugdex, 10th ed.

Denver: Micromedex Corp 1980. 5) Crismon ML, Evens RP. Lithium saliva levels. In: Conner C, ed. Drugdex, 10th ed.

Denver: Micromedex Corp 1980. 6) Crismon ML. Commentary on amoxapine. Pharmacotherapy 1981;1:177. 7) Raebel M, Crismon ML. Which benzodiazepine for sleep? Scott and White Pharmacy

Newsletter 1983;2:1-2. 8) Crismon ML. Clinical pathophysiology of organic brain syndromes. In: Wells B, ed.

Certificate program in psychiatric pharmacy practice, 2nd ed. Memphis: The University of Tennessee, 1983

9) Crismon ML (ed). TDMHMR Formulary 1985. Austin: Texas Department of Mental

Health and Mental Retardation, 1985. 10) Crismon ML. Pharmacists' perceptions of mentally ill patients. (letter) Am Jour Hosp

Pharm 1986;43:312. 11) Crismon ML. The legislature and you. TSHP Newsletter 1986;15(5):3. 12) Crismon ML. Making your P and T committee work for you. Hosp Formul 1987;22:103-

104. 13) Crismon ML. Planning for TSHP's financial future. TSHP Newsletter 1987;16(5):4.


Page 30 August 2016

14) Crismon ML. Implementing an effective drug usage evaluation program. Hosp Formul 1988;23:72-73.

15) Crismon ML. Treasurer's report. In: Texas Society of Hospital Pharmacists Annual

Report of 1987-88, Austin: Texas Society of Hospital Pharmacists, 1988: 3-6. 16) Crismon ML. Treasurer's report. In: Texas Society of Hospital Pharmacists Annual

Report of 1988-89, Austin: Texas Society of Hospital Pharmacists, 1989: 3-6. 17) Crismon ML. Higher education or education inflation. TSHP Newsletter 1989;18(6):2-3. 18) Crismon ML. Entry level education for pharmacists: debate continues over basic degree

requirement. The Dispenser 1989;44(Oct-Dec):1-2. 19) *Wasan S, Crismon ML. Considerations in establishing expiration dates for fluphenazine

multiple dose vials. DICP Ann Pharmacother 1990;24:889-90. 20) Crismon ML, Korek JS. Need. In: Batey SR, ed. A petition to the board of

pharmaceutical specialties requesting recognition of psychopharmacy practice as a specialty. Bethesda: American Society of Hospital Pharmacists, 1990:49-60.

21) Crismon ML. Making the distinction between clinical research and practice. APRS

Academy Reporter 1990;27(4):2-3. 22) Task Force on Specialty Recognition of Psychopharmacy Practice. Executive summary of

petition requesting recognition of psychopharmacy. Am J Hosp Pharm 1991;48:1284-90. 23) Crismon L. 1992 - The year in review. In: The Texas Society of Hospital Pharmacists

Research and Education Foundation Annual Report 1992, Clear Lake Shores: The Texas Society of Hospital Pharmacists Research and Education Foundation, 1992:3.

24) Crismon ML. President-elect's report. TSHP Newsletter 1993;22(4):1-2. 25) Crismon ML. Presidential address. TSHP Newsletter 1993;22(5):3-5, 8. 26) Crismon ML. President's message: Teamwork leads to legislative success. TSHP

Newsletter 1993;22(6):1, 4. 27) Crismon ML. President's message: Meeting the needs of pharmacists practicing in small

hospitals. TSHP Newsletter. 1993;22(7&8):1,4. 28) Crismon ML. President's message: The value of membership. TSHP Newsletter

1993;22(9&10):1-2. 29) Crismon ML. President's message: TSHP's 46th Annual Seminar and Exhibits:

something for everyone! TSHP Newsletter 1994;23(1):1,6.


Page 31 August 2016

30) *Eggert AE, Crismon ML. Current concepts in understanding Alzheimer's disease. Clinical Pharmacy Newswatch 1994;1(1):1-8.

31) Crismon ML. President's message: TSHP Newsletter marks another milestone. TSHP

Newsletter 1994;23(2):1. 32) Crismon ML. President's message: TSHP task force recommends formalized recognition

of the pharmacist's role in medication management. TSHP Newsletter 1994;23(3):1-2. 33) Crismon ML. Tacrine: a new drug for use in Alzheimer's disease. Alzheimer's

Association Newsletter 1994;(Winter):5. 34) Crismon ML. President's message: Celebrating a pathway to a new horizon. TSHP

Newsletter 1994;23(4):2,5.. 35) Crismon ML. President's report. TSHP Newsletter 1994;23(6):1-2. 36) *Still DJ, Crismon ML. Current and future directions in the pharmacotherapy of

depression. Clinical Pharmacy Newswatch 1994;1(5):1-8. 37) *Still DJ, Crismon ML. Pharmacoeconomics of depression. Clinical Pharmacy

Newswatch 1995;2(11):1-6. 38) Rush AJ, Rago B, Toprac M, Crismon ML, Stone S, Shon S. Toward the development of

medication algorithms for the treatment of major depressive, schizophrenic, and bipolar disorders - a white paper. Austin, TX: Texas Department of Mental Health and Mental Retardation, 1996, 29 pp.

39) Miller AL, Chiles JA, Chiles J, Crismon ML. TMAP procedural manual:

Schizophrenia module physician manual. Austin, TX: Texas Department of Mental Health and Mental Retardation, 1998. 59 pp.

40) Trivedi MH, Pigott T, Stegman K, O’Neal B, Baker S, Crismon ML, Rush AJ. TMAP

procedural manual: Depression module physician manual. Austin, TX: Texas Department of Mental Health and Mental Retardation, 1998. 142 pp.

41) Rush AJ, Crismon ML, Toprac M, Trivedi MH, Rago WV, Shon SP, Altshuler KZ.

Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998;59 (suppl 20):73-84.

42) Shon SP, Crismon ML, Toprac MG, Trivedi M, Miller AL, Suppes T, Rush AJ. Mental

health care from the public perspective: The Texas Medication Algorithm Project. J Clin Psychiatry 1999;60 (suppl 3):16-20.

43) Trivedi MH, Shon S, Crismon ML, Key T. TIMA procedural manual: depression

algorithms. Austin, TX: Texas Department of Mental Health and Mental Retardation, 1999. 50 pp.


Page 32 August 2016

44) Miller AL, Chiles JA, Chiles J, Crismon ML. TIMA procedural manual: schizophrenia algorithm. Austin, TX: Texas Department of Mental Health and Mental Retardation, 2000. 59 pp.

45) Crismon ML. Efficacy of atypical antipsychotics in schizophrenia. Informed Prescriber.

Merck-Medco Managed Care, LLC. 2000:1(1):1-4. 46) Starkweather K, Shon SP, Crismon ML. A Texas-sized prescription: providers report

progress with medication guidelines. Behavioral Healthcare Tomorrow 2000;9(4):44-46. 47) Crismon ML, Defilippi JL. Efficacy of antipsychotics in psychosis and behavioral

problems of dementia. Informed Prescriber. Merck-Medco Managed Care, LLC. 2000;1(2):1-4.

48) Crismon ML, Canales PL. Side effect profiles of antipsychotic medications: basis for

individualizing drug treatment. Part 1: typical antipsychotics. Informed Prescriber. Merck-Medco Managed Care, LLC. 2002;2(1):1-4.

49) Crismon ML, Canales PL. Side effect profiles of antipsychotic medications: basis for

individualizing drug treatment. Part 2: atypical antipsychotics. Informed Prescriber. Merck-Medco Managed Care, LLC 2002;2(2):1-4.

50) Miller AL, Hall CS, Crismon ML, Chiles J,. TIMA procedural manual: schizophrenia

algorithm. Austin, TX: Texas Department of Mental Health and Mental Retardation, 2003. 77 pp.

51) Crismon ML, Posey LM. FDA advisors: Black box warnings needed for SSRIs. TSHP

Journal 2004;5:45, 47. 52) Jensen PS, MacIntyre JC, Pappadopulos, EA (Eds). Treatment recommendations for the

use of antipsychotic medications for aggressive youth (TRAAY) – Pocket reference guide. New York: New York State Office of Mental Health and Columbia University, 2004: 38 pps.

53) Adair M, Burkett J, Crismon ML, Logan L, Lopez M, Muse N, Muzquiz-Drummond S,

Pliszka S, Robinson V, Shon S. Psychotropic medication utilization parameters for foster children. Austin, TX: Texas Department of State Health Services, 2005. 9 pps.

54) Fagan SC, Touchette D, Smith JA, Sowinski KM, Dolovich L, Olsen KL, Cheang KI,

Kolesar JM, Crismon ML. State of science and research in clinical pharmacy. A white paper from the Research Affairs Committee of the American College of Clinical Pharmacy. Pharmacotherapy 2006;26:1027-40.

55) Crismon ML. Clinical Psychopharmacology: Advances and Challenges from 1965 to

2006. Ann Pharmacother 2006;40:1649-1650.


Page 33 August 2016

56) Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M. CMAP ADHD and comorbid aggression algorithm. J Am Acad Child Adolesc Psychiatry 2007;46:2-3.

57) Crismon ML, Jensen P, Logan L, Lopez M, Machi A, Muse NJ, Muzquiz S, Pliszka SR,

Robinson V, Shon S. Psychotropic medication utilization parameters for foster children, 2nd ed.. Austin, TX: Texas Department of State Health Services, 2007. 12 pps. Available at http://www.dshs.state.tx.us/mhprograms/psychotropicMedicationFosterChildren.shtm

58) Crismon ML, Argo T, Bendele SD, Suppes T. Bipolar Disorder Algorithms, Update:

Texas Medication Algorithm Project. Austin, TX: Texas Department of State Health Services, 2007. 63 pps. Available at http://www.dshs.state.tx.us/mhprograms/TIMA.shtm

59) Crismon ML, Argo T, Bendele SD. Introduction to Algorithm-Based Care, WebTMAP,

The University of Texas at Austin, Austin, TX, 2007. https://www.WebTMAP.org

60) Crismon ML, Argo T, Bendele SD. Introduction to Brief Clinical Rating Scales, WebTMAP, The University of Texas at Austin, Austin, TX, 2007. https://www.WebTMAP.org

61) Crismon ML, Argo T, Bendele SD. The Bipolar I Disorder Algorithms, WebTMAP, The

University of Texas at Austin, Austin, TX, 2007. https://www.WebTMAP.org

62) Crismon ML, Argo T, Bendele SD. The Schizophrenia Algorithms, WebTMAP, The University of Texas at Austin, Austin, TX, 2007. https://www.WebTMAP.org

63) Crismon ML, Argo T, Bendele SD. The Depression Algorithms, WebTMAP, The

University of Texas at Austin, Austin, TX, 2007. https://www.WebTMAP.org

64) Crismon ML, Argo T, Bendele SD. Uniform Documentation, WebTMAP, The University of Texas at Austin, Austin, TX, 2007. https://www.WebTMAP.org

65) Argo TR, Crismon ML, Miller AL, Moore TA, Bendele SD, Suehs B. Schizophrenia

Treatment Algorithms, Texas Medication Algorithm Project Procedural Manual. Austin, TX: Texas Department of State Health Services, 2008. 62 pps. Available at http://www.dshs.state.tx.us/mhprograms/TIMA.shtm

66) Suehs B, Argo TR, Bendele SD, Crismon ML, Trivedi MH, Kurian B. Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. Austin, TX: Texas Department of State Health Services, 2008. 68 pps. Available at http://www.dshs.state.tx.us/mhprograms/TIMA.shtm

67) Crismon ML, Albright FS, Canney DJ, Das NG, Mehanna AS, Welage LS, Wu-Pong S.

The role of dual-degree programs in colleges and schools of pharmacy: The report of the 2008-09 Research and Graduate Affairs committee. Am J Pharm Educ 2009;73;S6:1-10.


Page 34 August 2016

68) Jensen P, Crystal S, Bendele S, Chait A, Correll C, Crismon ML, Findling R, Gerhard T, Gibson C, Hart K, Knapp P, Laraque D, Leslie LK, Lochman J, Lucas JA, Perkins M, Olfson M, Papadopoulos E, Rosato NS, Parker N, Wolraich M. Treatment of Maladaptive Aggression in Youth (T-MAY: The Rutgers Pocket Reference Guide for Primary Care Clinicians and Mental Health Specialists). New Brunswick, NJ: Center for Education and Research on Mental Health Therapeutics (CERTs), Rutgers University. 2010. 38 pps.

69) Crismon ML, Rogers JA, Jensen P, Clark LL, Fischer C, Hughes CW, Janes M, Martin JC, Martinez ON, Muse NJ, Muzquiz-Drummond S, Pliszka S, Schydlower M, Streusand WC. Psychotropic Medication Utilization Parameters for Foster Children, 3rd ed. Austin, TX. Texas Department of Family and Protective Services. 2010. 19 pps

70) Lau YS, Blouin R, Brixner D, Crismon L, Cutler S, Ho R, Jusko W, Nahata M, Sorkness C, Torchilin VP, Wu-Pong S. Report of the 2011-2012 AACP Special Advisory Committee on Research and Graduate Education. Am J Pharm Educ. 2012;12;76:S14.

71) Crismon ML. Pharmacist Graduation Competencies in a Transformed Healthcare Market – Implications for Psychiatric Pharmacy. Ment Health Clin. 2013;2(10):87. http://cpnp.org/resource/mhc/2013/04/pharmacist-graduation-competencies-transformed-healthcare-market-implications.

72) Crismon ML, Rogers JA, Allison DC, Becker E, Campbell, AH, , Janes M, Kratochvil CJ, Clark, LL, Lopez M, Martinez ON, Muse NJ, Muzquiz-Drummond S, Pliszka S, Schydlower M, Teutsch K. Psychotropic Medication Utilization Parameters for Children and Youth in Foster Care, 4th ed. Austin, TX. Texas Department of Family and Protective Services. 2013. 22 pages.

http://www.dfps.state.tx.us/Child_Protection/Medical_Services/guide-psychotropic.asp

73) Dipiro JT, Crismon ML, Evans RL Jr, Meyer SM, Eddington ND, Lau V. AACP Council of Deans report, 2013. Am J Pharm Educ 2013;77(9):S14. doi: 10.5688/ajpe

74) Crismon ML, Allen D, DiPiro JT, Brazeau G, Meyer SM, Lau V. Council of Deans Report, July 2014. Am J Pharm Educ 2014;7899):S17. doi: 10.5688/ajpe789S17.

75) Crismon ML, Rogers JA, Becker E, Blader J, Campbell AH, Janes M, Kratochvil CJ, Lopez M, Lukefahr J, Martinez ON, Muse NJ, Muzquiz-Drummond S, Pliszka S, Schatte D, Schydlower M. Psychotropic Medication Utilization Parameters for Children and Youth in Foster Care, 5th ed. Austin, TX. Texas Department of Family and Protective Services. 2016. 25 pages.

https://www.dfps.state.tx.us/Child_Protection/Medical_Services/guide-psychotropic.asp

( * Notes that author was a student or post-doctoral trainee.)

Abstracts: Dr. Crismon has been an author on 202 abstracts of papers presented at scientific and professional meetings, including the following since 1996.


Page 35 August 2016

71. *Canales PL, Dorson PG, Crismon ML. The effects of pharmaceutical care on clinical outcomes in an inpatient psychiatric setting. Abstracts of Alcalde X: Southwest Leadership Conference for Pharmacy Residents, Fellows and Preceptors 1996;10:PL IV-4.

72. *Canales PL, Dorson PG, Crismon ML. The effects of pharmaceutical care on clinical

outcomes in an inpatient psychiatric setting. Abstracts of the 31st Annual ASHP Midyear Clinical Meeting. International Pharmaceutical Abstracts 1996;33:2233.

73. *Llana ME, Crismon ML, Carey K, Wesnes KA. Cognitive effects of antidepressant

medication in children. Abstracts of the 31st Annual ASHP Midyear Clinical Meeting. International Pharmaceutical Abstracts 1996;33:2278.

74. Crismon ML. Dementia: the economic impact. Abstracts of the 31st Annual ASHP

Midyear Clinical Meeting. International Pharmaceutical Abstracts 1996;33:2330. 75. *Lee JW, Dorson PG, Crismon ML. Monitoring outcomes of recently released

antipsychotic medications. Abstracts of Alcalde XI: Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors 1997;11:PL II-4.

76. *Lee JW, Dorson PG, Crismon ML. Monitoring outcomes for recently released

antipsychotic medications in a state psychiatric hospital. Abstracts of the Texas Society of Health-System Pharmacists 49th Annual Seminar 1997;49:27.

77. *Canales PL, Dorson PG, Crismon ML. The effects of pharmaceutical care on clinical

outcomes in an inpatient psychiatric setting. Abstracts of the Texas Society of Health-System Pharmacists 49th Annual Seminar 1997;49:30.

78. Stanislav SW, Crismon ML, Childs N, Linnoila M. CSF monoamine metabolites and

post-traumatic aggression. Abstracts of the 52nd Annual Convention and Scientific Program of the Society of Biological Psychiatry. Biological Psychiatry 1997;41(suppl 7):357.

79. Shon S, Rush AJ, Altshuler K, Toprac M, Crismon ML. Texas Medication Algorithm

Project. Abstracts of the American Psychiatric Association Annual Meeting 1997.

80. Suppes T, Swann A, Crismon ML, Shon S, Rush AJ, Altshuler KZ. Will medication algorithms provide adequate information on treatment response in bipolar disorder? Abstracts of the 37th Annual NIMH New Clinical Drug Evaluation Unit Meeting 1997;37:77. Also published in Psychopharmacology Bulletin 1997;33:591.

81. Crismon ML, Shon S, Toprac M. Medication treatment algorithms (TMAP). Abstracts of

the 39th Annual Southern Regional Conference on Mental Health Statistics 1997:39:6.

82. Stanislav SW, *Keith M, Wesnes K, Crismon ML. Cognitive Drug Research Computerized Assessment System for Brain Injured Patients: A Validation Study. Abstracts of the 16th Annual National Brain Injury Symposium 1997;12:44.


Page 36 August 2016

83. Hamelin BA, Dorson PG, *Pabis D, *Still D, Turgeon J, Crismon ML. CYP2D6 mutations and therapeutic outcomes in schizophrenic patients. Abstracts of the American College of Clinical Pharmacy 1997 Annual Meeting. Pharmacotherapy 1997;17:1131.

84. *Canales PL, Dorson PG, Crismon ML. Assessment of psychiatric pharmacy services

outcomes. Abstracts of the 32nd Annual ASHP Midyear Clinical Meeting. International Pharmaceutical Abstracts 1997;34:2161.

85. Miller AL, Chiles JA, Rush AJ, Crismon ML, Toprac MG, Shore-Wilson KL. Medication

Algorithms for Schizophrenia. Abstracts of the Ninth Biennial Winter Workshop on Schizophrenia. Schizophrenia Research 1998;29:160.

86. Still DJ, *Llana ME, Dorson PG, Crismon ML. Nefazodone augmentation in the

treatment of resistant schizophrenia. Abstracts of Alcalde XII: Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors 1998;12:PL II-5.

87. *Defilippi JL, Crismon ML, Dorson PG. Evaluation of educational materials in an acute

psychiatric population. Abstracts of Alcalde XII: Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors 1998;12:PL II-8.

88. Shon, S, Toprac M, Crismon. ML. TMAP: An evaluation of the clinical and economic

impact of medication algorithms in public sector patients. Abstracts of the Annual Meeting of the Texas Council of Community MHMR Centers, 1998: 13.

89. Crismon ML. Rush AJ, Toprac MG, Shon S, Biggs MM, Shores-Wilson K, Mason M.

Texas Medication Algorithm Project; Feasibility study of implementing medication algorithms in the public mental health sector. Abstracts of the 3rd Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 1998;1:82.

90. Rush AJ, Crismon ML, Shon S, Toprac M, Altshuler KZ. Texas Medication Algorithm

Project: A status meeting 1998;38:48.

91. Hemlock C, *Kipping DA, Crismon ML. Evaluation of mood and anxiety disorders and alcohol abuse in a medical follow-up clinic using the Prime-MD. Abstracts of the 38th Annual NIMH New Clinical Drug Evaluation Unit Meeting 1998;38:54.

92. Trivedi MH, Crismon ML, Piggott T, Shon S, Rush AJ. Texas Medication Algorithm

Project: Depression module. Abstracts of the 38th Annual NIMH New Clinical Drug Evaluation Unit Meeting 1998;38:54:172.

93. Miller AL, Chiles JA, Rush AJ, Biggs MM, Crismon ML, Mason M. Medication

algorithms for schizophrenia: development, implementation, and modification. Abstracts of the XXIst CINP Congress 1998;21:PT07080.

94. Rush AJ, Crismon ML, Miller AL, Suppes T, Trivedi MH, Toprac MG, Shon SP, Kashner

MT, Altshuler KZ. The Texas Medication Algorithm Project (TMAP): A status report.


Page 37 August 2016

Abstracts of the 50th Institute of Psychiatric Services. American Psychiatric Association, 1998.

95. Nwangwu VU, Crismon ML, Ingham DA, Stakem R. Establishment of a clinical

psychopharmacology center for community mental health. Abstracts of the 33rd Annual ASHP Midyear Clinical Meeting. 1998;33:FGF-6. International Pharmaceutical Abstracts 1998;35:2235.

96. *Defilippi JL, Crismon ML, Dorson PG. Evaluation of educational materials in an acute

care psychiatric population. Abstracts of the 33rd Annual ASHP Midyear Clinical Meeting. 1998;33:P-213E. International Pharmaceutical Abstracts 1998;35:2238.

97. Brown ES, Suppes T, Swann AC, Rush AJ, Crismon ML, Shon S, Toprac MG, Kashner

TM, Altshuler KZ. The Texas Medication Algorithm Project Bipolar Disorder Module: A status report. Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology, 1998;37:195.

98. Trivedi MH, Crismon ML, Pigott T, Shon S, Rush AJ. Texas Medication Algorithm

Project: Depression Module. Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology, 1998;37:321.

99. *McKeithan-Richards K, Shepherd MD, Crismon ML. Cost of illness of Alzheimer’s

disease and the relationships among costs, time, and caregiver burden. Abstracts of the 1999 Annual Meeting of the American Pharmaceutical Association. J Am Pharm Assoc 1999;39:268-69.

100. *Bettinger T, Crismon ML, Dorson PG, Edge SC. Weight gain associated with atypical

antipsychotics. Abstracts of Alcalde XIII: Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors. 1999;13:PL IV-9.

101. *Baumgartner JL, Crismon ML, Dorson PG, Edge SC. Evaluation of monthly medication

regimen reviews in an extended care psychiatric setting. Abstracts of Alcalde XIII: Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors. 1999;13:PL VI-6.

102. Crismon ML, Rush AJ, Toprac MG, Shon SP, Miller AL, Suppes T, Trivedi MH. Texas

Medication Algorithm Project: Feasibility study of implementing algorithms in the public mental health sector. Abstracts of the 2nd Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists 1999;2:10.

103. Crismon ML, Rush AJ. Issues in guideline development. Symposium entitled: Texas

Medication Algorithm Project: update. Syllabus and Proceedings of the American Psychiatric Association’s 51st Institute on Psychiatric Services. 1999;51:190.

104. Miller AL, Chiles JA, Shores-Wilson K, Biggs MM, Podawitz A, Crismon ML, Shon S,

Mason M, Rush AJ. Feasibility trial of the schizophrenia algorithm in TMAP. Abstracts of the Tenth Biennial Workshop on Schizophrenia. February 5-11, 2000.


Page 38 August 2016

105. Richards KM, Shepherd MD, Crismon ML, Snyder EH. Alzheimer’s disease cost of care in managed care. Abstracts of the 5th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2000;3:78.

106. Crismon ML. Treatment algorithms for the management of depressive illness.

Symposium entitled: Management of Depression: Current Practice and Future Directions. Abstracts on the 35th Annual ASHP Midyear Clinical Meeting 2000;35:PI-84.

107. *Patel NC, Crismon ML, Rush AJ, Frances A. A comparative study of practicing

psychiatrists with the expert consensus panel regarding pharmacotherapy of the mentally retarded with mental disorders. Abstracts on the 35th Annual ASHP Midyear Clinical Meeting 2000;35:P-581E.

108. *Edwards NJ, Dorson PG, Mendelson SC, Mason M, *Patel NC, Crismon ML.

Readmission rates using the atypical antipsychotics versus the traditional antipsychotics. Abstracts on the 35th Annual ASHP Midyear Clinical Meeting 2000;35:P-589R.

109. *Pondrom MF, Dorson PG, Mendelson SC, Mason M, *Patel NC, Crismon ML.

Rehospitalization rates of mood stabilizer monotherapy compared with combination therapy with an atypical antipsychotic. Abstracts on the 35th Annual ASHP Midyear Clinical Meeting 2000;35:P-590R.

110. Rush AJ, Shon SP, Crismon ML, Toprac MG, Miller AL, Trivedi MH, Suppes T, Kashner

TM, Carmody TJ. The Texas Medication Algorithm Project (TMAP): Results of a 3 year study. Panel Session entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. Abstracts of the American College of Neuropsychopharmacology 2000 Annual Meeting 2000;39:22.

111. Crismon ML, Rush AJ, Toprac MG, Shon SP, Miller AL, Suppes T, Kashner, TM,

Carmody TJ, Biggs MM, Shores-Wilson K, Altshuler KZ.. TMAP study methodology. Panel Session entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. Abstracts of the American College of Neuropsychopharmacology 39th Annual Meeting 2000;39:22.

112. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Kashner TM, Toprac MG,

Shores-Wilson K, Biggs MM, Witte B, Carmody TJ, Shon SP. The Texas Medication Algorithm Project (TMAP): Outcomes for persons with schizophrenia. Panel Session entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. Abstracts of the American College of Neuropsychopharmacology 39th Annual Meeting 2000;39:23.

113. Suppes T, Dennehy EB, Rush AJ, Crismon ML, Toprac MG, Kashner TM, Carmody TJ,

Brown ES, Shores-Wilson K, Biggs MM, Witte B, Shon SP. The Texas Medication Algorithm Project (TMAP): Outcomes for persons with bipolar disorder. Panel Session entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. Abstracts of the American College of Neuropsychopharmacology 39th Annual Meeting 2000;39:23.


Page 39 August 2016

114. Trivedi MH, Rush AJ, Crismon ML, Key T, Kashner TM, Biggs MM, Shores-Wilson K, Toprac MG, Carmody TJ, Witte B, Pigott T, Shon SP. The Texas Medication Algorithm Project (TMAP): Outcomes for persons with major depressive disorder. Panel Session entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. Abstracts of the American College of Neuropsychopharmacology 39th Annual Meeting 2000;39:24.

115. *Craig CS, Dorson PG, Mendelson SC, Crismon ML. Valproate as an adjunct in

schizophrenia. Abstracts of Alcalde XV, Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors 2001;15:PL III-8.

116. *Seiler MR, Dorson PG, Crismon ML. Outcomes associated with atypical antipsychotic

polypharmacy. Abstracts of Alcalde XV, Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors 2001;15:PL V-7.

117. *Baumgartner JL, Crismon ML, Lopez M, Toprac M. Evaluation of a patient and family

education program for children and adolescents with ADHD. Abstracts of the 4th Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists. 2001;4:34.

118. *Bettinger TL, Crismon ML, Trivedi MH, Shon S. Implementation of a medication

algorithm. Abstracts of the 4th Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists. 2001;4:35.

119. Johnsrud M, Crismon ML. Risperidone and olanzapine utilization and expenditures

within the Texas Medicaid program. Abstracts of the 2001 Annual Meeting of the Academy of Managed Care Pharmacy.

120. Miller, AL, Chiles, JA, Chiles, JK, Crismon, ML, Rush, J, Kashner, M, Shon, SP. The

Texas Medication Algorithm Project (TMAP): Outcomes for persons with schizophrenia. Schizophrenia Research, 2001;49:239.

121. *Patel NC, Crismon ML, Rush AJ, Frances A. A comparative study of practicing

psychiatrists with the expert consensus panel regarding pharmacotherapy of the mentally retarded with mental disorders. Abstracts of the 2001 American Psychiatric Association Annual Meeting 2001;NR530:144.

122. Johnsrud M, Crismon ML, Thompson A, Grogg A. Risperidone and olanzapine

utilization and expenditures within the Texas Medicaid program. Abstracts of the 2001 American Psychiatric Association Annual Meeting 2001;NR703:190.

123. Crismon ML. Issues and tensions in specifying and developing medication algorithms.

Abstracts of the 2001 American Psychiatric Association Annual Meeting 2001;23B.

124. Rascati KL, Johnsrud M, Crismon ML, Barber BK, Lage MJ. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Abstracts of the 5th Annual Meeting of the International Society for


Page 40 August 2016

Pharmacoeconomics and Outcomes Research 2001;5:PMH33. Also published in Value in Health 2001;4:151.

125. *Baumgartner JL, Emslie GJ, Crismon ML. Citalopram use in 17 children and

adolescents: a case series. Abstracts of the 41st Annual NIMH New Clinical Drug Evaluation Unit Meeting 2001;41:I-26.

126. *Patel NC, Dorson PG, *Edwards N, Mendelson S, Mason M, Crismon ML.

Rehospitalization rates with atypical antipsychotics versus traditional antipsychotics. Abstracts of the 41st Annual NIMH New Clinical Drug Evaluation Unit Meeting 2001;41:III-69.

127. Johnsrud M, Crismon ML, Thompson A, Grogg A. A comparison of expenditures by

indigent patients continuously treated with atypical antipsychotic agents within a behavioral health organization in Texas. Abstracts of the 41st Annual NIMH New Clinical Drug Evaluation Unit Meeting 2001;41:II-69.

128. Rascati KL, Johnsrud M, Crismon ML, Barber BK, Lage MJ. Costs associated with the

use of atypical antipsychotics. Abstracts of the 7th World Congress of Biological Psychiatry. World Federation of Societies of Biological Society. 2001;7:PO21-65.


indigent patients continuously treated with atypical antipsychotic agents within a behavioral health organization in Texas. Syllabus and Proceedings of the American Psychiatric Association’s 53rd Institute on Psychiatric Services, 2001.

130. Johnsrud MT, Crismon ML. Economic comparison of SSRI use and expenditures among

clients in the Texas Medicaid Program. Abstracts of the Academy of Managed Care Pharmacy 2001 Educational Conference Journal of Managed Care Pharmacy 2001;7:364.

131. Crismon ML, Trivedi MH, Rush AJ, Kashner TM, Toprac MG, Biggs MM, Shores-

Wilson K, Carmody TJ, Shon SP. The Texas Medication Algorithm Project (TMAP): Outcomes for persons with major depressive disorder. Abstracts of the American College of Clinical Pharmacy 2001 Annual Meeting. 2001;535.


indigent patients continuously treated with atypical antipsychotic agents within a behavioral health organization in Texas. Abstracts of the American College of Clinical Pharmacy 2001 Annual Meeting. 2001;535.

133. *Baumgartner JL, Crismon ML, Lopez M. Evaluation of a patient and family education

program for children and adolescents with attention deficit hyperactivity disorder. Abstracts of the American College of Clinical Pharmacy 2001 Annual Meeting. 2001;356.

134. Emslie GJ, Pliszka S, Crismon ML, Hughes CW, Lopez M, Toprac M, Ellis C. Lessons

learned from the Children’s Medication Algorithm Project. Scientific Proceedings of the


Page 41 August 2016

48th Annual Meeting of the American Academy of Child & Adolescent Psychiatry 2001;48:70.

135. Crismon ML Overview of algorithms: consensus to CMAP. Scientific Proceedings of the

48th Annual Meeting of the American Academy of Child & Adolescent Psychiatry 2001;48:70-1.

136. *Bettinger TL, Crismon ML, Trivedi MH, Shon S. Implementation of a medication

algorithm for major depressive disorder. Abstracts of the Annual Meeting of the American Association of Pharmaceutical Scientists 2001;T3779.

137. Dennehy, EB, Suppes T, Crismon ML, Rush AJ. The measurement of adherence to a

treatment guideline for bipolar disorder. Abstracts of the 40th annual meeting of the American College of Neuropsychopharmacology, December 9-13, 2001.

138. Miller AL, Chiles JA, Rush AJ, Crismon ML, Kashner TM, Carmody T, Toprac M,

Thomas C, Biggs M, Shores-Wilson K, Velligan DI, Suppes T, Trivedi M, Shon S. TMAP: Outcomes with schizophrenia. Schizophrenia Research 2002;53(suppl S):206.

139. *Stewart JL, Crismon ML, Lee JW, Finney TW. Weight gain in children and adolescents

receiving antipsychotics. Abstracts of Alcalde XVI, Southwest Leadership Conference. TSHP Journal 2002;3:70.

140. *Cala S, Crismon ML, *Baumgartner JL. Use of herbal medicines in children with

ADHD or depressive disorders. Abstracts of the 2002 Annual Meeting of the American Psychiatric Association, May 22, 2002.

141. *Patel NC, *Sanchez RJ, Johnsrud MT, Crismon ML. Trends in antipsychotic use in

children and adolescents: 1996-2000. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:I-68; also published in Jour Child & Adolesc Psychopharm 2002;12:289.

142. Crismon ML, Lopez M, Emslie GJ, Pliszka SR, Toprac MG, Hughes CW, Boemer C. The

Children’s Medication Algorithm Project (CMAP) phase II: results of a feasibility study. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:I-69; also published in Jour Child & Adolesc Psychopharm 2002;12:289-90.

143. Dennehy, EB, Suppes T, Crismon ML, Rush AJ. The Texas Medication Algorithm

Project: physician adherence to a medication algorithm for treatment of bipolar disorder. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:I-71.

144. Johnsrud M, Grogg A, Crismon ML. A comparison of the economic impact of adjunctive

atypical antipsychotic use in bipolar disorder. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:I-81.

145. *Cala S, Crismon ML, *Baumgartner JL. Use of herbal medicines in children with

ADHD or depressive disorders. Abstracts of the 42nd Annual NIMH New Clinical Drug


Page 42 August 2016

Evaluation Unit Meeting 2002;42:II-12; also published in Jour Child & Adolesc Psychopharm 2002;12:291-92.

146. Velligan DI, Prihoda TJ, Dennehy, EB Biggs MM, Shores-Wilson K, Crismon ML, Rush

AJ, Miller AL, Suppes T, Trivedi M, Kashner TM, Shon S, Witte BS, Toprac M, Carmody T. The factor structure of the Brief Psychiatric Rating Scale expanded version in a large diverse sample of psychiatric patients. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:II-48.

147. *Baumgartner JL, Crismon ML, Lopez M. Evaluation of a patient and family education

program for children and adolescents with attention deficit hyperactivity disorder. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:II-60.

148. *Bettinger TL, Crismon ML, Trivedi M, Grannemann B, Shon S. Clinician adherence to a

major depressive disorder algorithm in the Texas public mental health sector. Abstracts of the 42nd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2002;42:III-86.

149. Johnsrud M, Crismon ML, Thompson A, Grogg A. Risperidone and olanzapine use

within a behavioral health organization. Abstracts of the American Psychiatric Association 54th Annual Institute on Psychiatric Services 2002.

150. Jensen PS, Crismon ML, Bickman L, McHugo G, Pappadopulos E. The science behind

developing, disseminating, and implementing practice guidelines. Abstracts of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry 2002;49:78.

151. Crismon ML, Rush A, Miller A, Suppes T, Trivedi M, Toprac M, Kashner M, Shon S.

Lessons learned from the Texas Medication Algorithm Project (TMAP). Symposium entitled: The Science Behind Developing, Disseminating, and Implementing Practice Guidelines. Abstracts of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry 2002;49:79.

152. *Chuang WC, Crismon ML. Evaluation of the implementation of the Texas

Implementation of Medication Algorithms (TIMA) schizophrenia algorithm in a state hospital. Abstracts of the 37th Annual ASHP Midyear Clinical Meeting 2002.

153. Dassori AM, Velligan DI, Prihoda TJ, Miller AL, Chiles JA, Rush J, Shores-Wilson K,

Biggs M, Crismon ML. Ethnic/racial comparisons in symptomatology in a large sample of patients with schizophrenia in Texas. Schizophrenia Research 2003;60;1 (March suppl):14.

154. Prihoda TJ, Miller AL, Velligan D, Bow-Thomas C, Biggs M, Shores-Wilson K, Carmody

T, Crismon L, Rush AJ. Clinical predictors of cognitive function change in schizophrenia. Schizophrenia Research 2003;60;1 (March suppl):152-3.

155. *Clark K, Mican L, Crismon ML. Olanzapine monotherapy vs. olanzapine plus valproic

acid for bipolar disorder. Abstracts of Alcalde XVII: Southwest Leadership Conference 2003;17:PL I-4. Also published in TSHP Journal 2003;4:40.


Page 43 August 2016

156. *Lane DC, *DeLeon A, *Patel NC, Lopez M, Crismon ML. Risperidone for the treatment

of schizophrenia in children and adolescents: an ethnic perspective. Abstracts of the 2003 Annual Meeting of the American Psychiatric Association 2003;156:30.

157. Miller AL, Kashner TM, Crismon ML, Chiles JA, Trivedi MT, Suppes P, Rush AJ.

Resource utilization by schizophrenia patients in TMAP. Abstracts of the 2003 Annual Meeting of the American Psychiatric Association 2003;156:153.

158. *Patel NC, Crismon ML, *Pondrom M. Rehospitalization rates of patients with bipolar

disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical antipsychotic. Abstracts of the 2003 Annual Meeting of the American Psychiatric Association 2003;156:161.

159. *DeLeon A, *Lane DC, *Patel NC, Lopez M, Crismon ML. A naturalistic comparison of

olanzapine and risperidone in children and adolescents with schizophrenia. Abstracts of the 2003 Annual Meeting of the American Psychiatric Association 2003;156:262.

160. *Patel NC, Crismon ML, *Pondrom M. Rehospitalization rates of patients with bipolar

disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical antipsychotic. Abstracts of the 43rd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2003;43:147.

161. Suppes T, Kashner TM, Dennehy EB, Toprac M, Crismon ML, Shon S, Rush AJ. Service

utilization among patients with bipolar disorder in the Texas Medication Algorithm Project. Abstracts of the 43rd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2003;43:162.

162. *DeLeon A, *Lane DC, *Patel NC, Lopez M, Crismon ML. A naturalistic comparison of

olanzapine and risperidone in children and adolescents with schizophrenia. Abstracts of the 43rd Annual NIMH New Clinical Drug Evaluation Unit Meeting 2003;43:217; also published in Jour Child & Adolesc Psychopharm 2003;13:423.

163. *Hartnell NR, Wilson JP, *Patel NC, Crismon ML. Selective serotonin reuptake

inhibitors: a new phenomenon associated with spontaneous adverse event reporting. Abstracts of the International Society of Pharmacoepidemiology 19th International Conference for Pharmacoepidemiology/1st International Conference on Therapeutic Risk Management 2003.

164. *Hartnell NR, Wilson JP, *Patel NC, Crismon ML. Selective serotonin reuptake

inhibitors: a new phenomenon associated with spontaneous adverse event reporting. Abstracts of Canadian Society for Epidemiology and Biostatistics Biennial Meeting 2003.

165. Johnsrud M, Grogg A, Crismon ML. A comparison of the economic impact of adjunctive

antipsychotic use in bipolar disorder. Abstracts of the Academy of Managed Care Pharmacy 2003 Educational Conference, JMCP 2003;9:464.


Page 44 August 2016

166. *Sanchez R, Crismon ML, Barner JC, Wilson JP, Bettinger T. Adherence measures of psychostimulants in children and adolescents with attention deficit hyperactivity disorder (ADHD). Journal of the American Pharmacists Association 2004;44:232.

167. *Hunziker ME, *Patel NC, Crismon ML, *DeLeon A, Shafer A, Bettinger T. Symptom

profiles of children with a diagnosis of ADHD, bipolar disorder, or a depressive disorder. Abstracts of Alcalde XVIII 2004;18:PL-I-1.

168. *Dominguez RI, Mican LM, *Patel NC, Bettinger T, Crismon ML. Evaluation of an

inpatient psychopharmacology consult service. Abstracts of Alcalde XVIII 2004;18:PL-I-6.

169. Bainbridge J, May F, Crismon L. Around the world – implementing clinical guidelines

into practice. Abstracts of the 2nd ACCP – ESCP International Congress on Clinical Pharmacy, Paris, France 2004:43.

170. *Patel NC, Crismon ML, Hoagwood KE, Johnsrud MT, Rascati KL, Wilson JP. Trends in

antipsychotic prescribing to children and adolescents: 1996 to 2001. Abstracts of the 8th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2004;7:282.

171. *Patel NC, Crismon ML, Miller AL, Johnsrud MT. Adherence to clozapine: effects of

reduced visit frequency. Abstracts of the 44th Annual NIMH New Clinical Drug Evaluation Unit Meeting 2004;44:294.

172. *Hunziker ME, *DeLeon A, *Patel NC, Crismon ML, Shafer A, Bettinger T.

Symptom profiles of children and adolescents with a diagnosis of ADHD, bipolar disorder, or depressive disorder. Abstracts of the 44th Annual NIMH Annual New Clinical Drug Evaluation Meeting 2004;44:58; also published in Jour Child & Adolesc Psychopharm 2004;14:509-10.

173. *Sanchez RJ, Crismon ML, Barner JC, Wilson JP, Bettinger T. Adherence measures of

psychostimulants in children and adolescents with attention deficit hyperactivity disorder (ADHD). Abstracts of the 44th Annual NIMH Annual New Clinical Drug Evaluation Meeting 2004;;44:61; also published in Jour Child & Adolesc Psychopharm 2004;14:511.

174. Crismon ML, *Patel NC, Hoagwood KE, Johnsrud MT, Rascati KL, Wilson JP. Trends in

antipsychotic prescribing to children and adolescents: 1996 to 2001. Abstracts of the 44th Annual NIMH Annual New Clinical Drug Evaluation Meeting 2004;44:156; also published in Jour Child & Adolesc Psychopharm 2004;14:520.

175. Crismon ML, *Patel N, Hoagwood K, Johnsrud M, Rascati K, Wilson J. Prescribing

practices associated with antipsychotic use in Texas Medicaid youths [poster:B45]. Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child & Adolescent Psychiatry 2004:125.

176. Crismon ML, *Patel NC, Hoagwood KE, Johnsrud MT, Rascati KL, Wilson JP.

Prescribing practices associated with antipsychotic use in Texas Medicaid youths.


Page 45 August 2016

Abstracts of the 2004 Annual Meeting of the American College of Clinical Pharmacy, published in Pharmacotherapy 2004;24:1463.

177. Johnsrud M, Crismon ML, Pesa J, Sasane RM, Atypical Antipsychotics in the Treatment

of Dementia among Texas Medicaid Enrollees. Abstracts of the American Association of Geriatric Psychiatry Annual Meeting. San Diego, CA, March 5, 2005.

178. Crismon ML, *Lau C, *Patel NC, Mican LM. Naturalistic evaluation of intramuscular

ziprasidone versus haloperidol use in acute aggression. Abstracts of the 2005 Annual Meeting of the Academy of Managed Care Pharmacy 2005;17:24.

179. Miller A, DiCocco MA, Kashner TM, Crismon ML, Chiles JA. Adherence to TMAP

guidelines for treatment of schizophrenia. Schizophrenia Bulletin 2005;31:545-546.

180. *DeLeon A, Crismon ML, Miller AL, Lawson KA, Bettinger TL. Antipsychotic polypharmacy: Pharmacoepidemiology and potential predictors of utilization. Abstracts of the 45th Annual NIMH NCDEU Meeting 2005;45:220.

181. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR,

Crismon ML, Ketter T, Sachs G, Swann AC.. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar disorder. Abstracts of the 45th Annual NIMH NCDEU Meeting 2005;45:278.

182. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR,

Crismon ML, Ketter T, Sachs G, Swann AC.. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar disorder. Abstracts of the 6th International Conference on Bipolar Disorder; also published in Bipolar Disorders 2005;7(suppl 2):104.

183. Crismon ML, Kashner TM, Rush AJ, Suppes T, Toprac M, Carmody TJ, Wicker BA.

Cost-outcome for patients with bipolar disorder in the Texas Medication Algorithm Project (TMAP). Abstracts of the 18th NIMH Conference on Mental Health Services Research 2005;18 (Panel Abstracts):3.

184. Bettinger T, Johnsrud M, Crismon ML. Off label prescribing of atypical antipsychotics.

Abstracts of the 9th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, 2006.

185. *Yang M, Barner JC, Rascati KL, Lawson KA, Wilson JP, Crismon ML, Worchel J,

Mascarenas C. Antipsychotic utilization and treatment-emergent diabetes – A methodological comparison using a claims database. Abstracts of the 10th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2006;9(3):A38-A39.

186. *Yang M, Barner JC, Rascati KL, Lawson KA, Wilson JP, Crismon ML, Worchel J,

Mascarenas C. Antipsychotic utilization and treatment-emergent diabetes – Comparison of results with and without propensity scoring. Abstracts of the 10th Annual Meeting of the


Page 46 August 2016

International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2006;9(3):A39.

187. *Harrington P, Barner JC, Crismon ML, Lawson KA, Mascarenas C, Rascati KL.

Incident diabetes associated with use of second-generation antipsychotic (SGA) therapy: An evaluation of the impact of dose and treatment indication. Abstracts of the 10th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2006;9(3):A65.

188. *Harrington P, Barner JC, Crismon ML, Lawson KA, Mascarenas C, Rascati KL.

Demographic and clinical characteristics of patients prescribed antipsychotic (AP) monotherapy in Texas Medicaid. Abstracts of the 10th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2006;9(3):A74..

189. *Gibson AP, *Hunziker M, Mican LM, Crismon ML,. Retrospective evaluation of

aripiprazole in child and adolescent psychiatric inpatients. Abstracts of the 46th Annual NIMH NCDEU Meeting. 2006;46:225.

190. Robinson DG, Schooler NR, Crismon ML, McEvoy P. Treatment of first-episode

schizophrenia. Schizophrenia Bulletin 2007;33:456.

191. *Gibson AP, Crismon ML, Johnsrud M, Lawson K, Allgeyer R. Comparison of mental illness prevalence and treatment patterns between foster and non-foster children within the Texas Medicaid system. Poster Abstracts of the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists 2007;10:1.

192. *Hughes AD, *Suehs BT, Crismon ML, *Anupindi RM. Prescribing patterns in children

and adolescents with bipolar disorder. Poster Abstracts of the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists 2007;10:3.

193. *Perry R, Argo T, Mican L, Crismon ML. A retrospective evaluation of physician

prescribing habits in children and adolescents with mental retardation and bipolar disorder. Poster Abstracts of the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists 2007;10:78.

194. Argo TR, Crismon ML, Bendele SD, Donovan M. Development of a web-based clinician

learning program for algorithm-based care of adults with major mental illnesses: the Web-Texas Medication Algorithm Project (Web-TMAP). Poster Abstracts of the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists 2007;10:95.

195. Donovan M, Crismon ML, Argo TR. Just what did the doctor prescribe? A performance

improvement case study. Abstracts of the 2007 International Performance Improvement Conference 2007;45:38.

196. *Gibson AP, Crismon ML, Johnsrud M, Lawson K, Allgeyer R. A comparison of mental

illness and treatment type prevalence between foster and non-foster children within the


Page 47 August 2016

Texas Medicaid system. Abstracts of the 47th Annual NIMH NCDEU Meeting. 2007;47:49.

197. *Hughes AD, *Suehs BT, Crismon ML, *Anupindi RM. Prescribing patterns in children

and adolescents with bipolar disorder. Abstracts of the 47th Annual NIMH NCDEU Meeting. 2007;47:151.

198. Lawson KA., Johnsrud MT, Sasane R, Hodgkins P, Crismon ML. Attention-

Deficit/Hyperactivity Disorder (ADHD) medication utilization and expenditures in the Texas Medicaid Program: Comparison by Medication Class. Abstracts of the European Psychiatric Association 18th European Congress of Psychiatry, Munich, Germany, February 27-March 2, 2010.

199. Lawson KA., Johnsrud MT, Sasane R, Hodgkins P, Crismon ML. Utilization and

expenditures for lisdexamfetamine compared to other Attention Deficit/Hyperactivity Disorder (ADHD) medication classes in the Texas Medicaid Program. Abstracts of the European Psychiatric Association 18th European Congress of Psychiatry, Munich, Germany, February 27-March 2, 2010.

200. *Fowler JA, Barner JC, Crismon ML, Argo TR, Smith TL. A retrospective evaluation of

the relationship between mental disorders and patient adherence to antiretroviral therapy. Abstracts of the 2010 Annual Meeting of the College of Psychiatric and Neurologic Pharmacists. Journal of Pharmacy Practice 2010;23:149-50.

201. *Fowler JA, Barner JC, Crismon ML, Argo TR, Smith TL. A retrospective evaluation of patient adherence to antiretroviral therapy: Proportion of days covered versus medication possession ratio. Abstracts of the 15th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health 2010;13:A193.

202. Crismon ML, Rogers JA, Shafer A. Development of Psychotropic Medication Utilization Parameters for Foster Children. Abstracts of the 14th Annual Meeting of the College of Neurologic and Psychiatric Pharmacists. Journal of Pharmacy Practice 2011;24(2):281-282.

203. Crismon ML. Rogers JA, Shafer A, Muse NJ. Evaluation of implementation of psychotropic medication utilization parameters for children and adolescents in Texas foster care. Abstracts of the ASCP Annual Meeting. 2014; page 89, poster #60. http://ascpmeeting.org/wp-content/uploads/2014/06/Poster-Abstracts-FINAL.pdf

204. Crismon ML. Perspectives on the future of pharmacy practice and pharmacy education. Dubai International Pharmaceuticals & Technologies Conference (DUPHAT) Official Catalogue. 2015; page 78.

205. Crismon ML. Improving the use of psychotropic medication in children and youth. Dubai International Pharmaceuticals & Technologies Conference (DUPHAT) Official Catalogue. 2015; page 113.

( * Notes that the author was a student or post-doctoral trainee.)


Page 48 August 2016

Book Reviews

Crismon ML. [Jefferson JW, Greist JH, Ackerman DL. Lithium encyclopedia for clinical practice. Washington: American Psychiatric Press, 1983], Clinical Pharmacy 1984;3:99.

Crismon ML. [Feldman RS, Quenzer LF. Fundamentals of neuropsychopharmacology.

Sunderland: Sinauer Associates, 1984], Drug Intell Clin Pharm 1984;18:754. Crismon ML, Jermain DM. [Ginsberg MD, Dietrich WD. Cerebrovascular diseases: 16th

research (Princeton) conference. New York: Raven, 1989], DICP: Annals Pharmacother 1990;24:103.

Crismon ML. [Williams RL, Brater DC, Mordenti J (Eds). Rational therapeutics: A clinical

pharmacologic guide for the health professional. New York: Marcel Dekker, 1990], Toxicology Letters 1990;53:349-50.

Ginsburg DB, Crismon ML. [Strauss S (ed). Strauss' pharmacy law examination review.

Lancaster, PA:Technomic, 1991], Am J Hosp Pharm 1991;48:2537. Crismon ML. [Waxman SG (ed). Molecular and cellular approaches to the treatment of

neurological disease. New York: Raven, 1993], Annals Pharmacother 1994;28:975-76. Crismon ML. [Heifetz MD. Easier said than done: moral decisions in medical uncertainty.

Buffalo: Promethus, 1992], Am J Health-Syst Pharm 1995;52:570-71.

EDITORIAL RESPONSIBILITIES Abstractor for "Abstracts from the Pharmaceutical and Medical Literature" US Pharmacist,

1978-79 Member, Editorial Review Board, Smith DL. Understanding Prescription Drugs, New York:

Pocket Books, 1986, 2nd edition, 1987.

Chairman, Panel on Neurology, Editorial Advisory Board, The Annals of Pharmacotherapy, 1989-93.

Member, Editorial Board, Clinical Pharmacy Newswatch, 1994. Member, Advisory Board, Mental Health and Pharmacy, Drug Topics, 1997-98. Member, Editorial Advisory Board, Special Report on Alzheimer’s Disease, American

Pharmaceutical Association, 1999


Page 49 August 2016

Member, Editorial Board for the Guidelines. Rush AJ, Frances A (ed). Expert Consensus Guideline Series. Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation 2000;105:159-238.

Associate Editor, The American Pharmaceutical Association Drug Treatment Protocols, 2nd ed.

(Albrandt, DH, ed.). Washington, DC: American Pharmaceutical Association, 2001, 487 pps.

Crismon ML (chair), Banerji MA, Casey DA, Ereshefsky L, eds. APhA Special Report:

Medication management considerations in schizophrenia, American Pharmaceutical Association, Washington, D.C., 2002:21 pps.

Aman MG, Crismon ML, Frances A, King BH, Rojahn J, eds. Treatment of psychiatric and

behavioral problems in individuals with mental retardation: An update of the expert consensus guidelines, Postgraduate Institute for Medicine, Englewood, CO, 2004:20 pps.

Member, Editorial Advisory Board, The Annals of Pharmacotherapy (formerly Drug

Intelligence and Clinical Pharmacy ), 1985 - 2013.

Member, Editorial Advisory Board, DrugINFOLine, American Pharmaceutical Association, Washington, D.C., 2000 - present.

Member, Editorial Advisory Board, Journal of the American Pharmacists Association, 2014-17. I have reviewed for the following:

Publications AHFS Drug Information

Journal of the American Pharmaceutical Association American Journal of Health-System Pharmacy American Journal of Pharmaceutical Education American Journal of Psychiatry Annals of Pharmacotherapy Archives of General Psychiatry

Biological Psychiatry Clinical Pharmacy Clinical Therapeutics CNS Drugs Current Medical Research and Opinion Current Psychiatry Handbook of Nonprescription Drugs, Hospital Formulary Journal of Behavioral Health Services & Research Journal of Child and Adolescent Psychopharmacology Journal of Clinical Psychiatry Journal of Clinical Psychopharmacology Lexicon of Psychiatry, Neurology, and Neurosciences


Page 50 August 2016

Pharmacotherapy Psychiatric Services Psychological Medicine U.S. Pharmacist The Lancet

Grant and Awards Programs AACP Young Investigators Awards Program, 1992 ACCP Foundation Mead Johnson CNS Research Award Program, 1990. ACCP Foundation Psychopharmacy Research Fellowship, 1997, 2002 ASHP Foundation Demonstration Projects Grant Program, 1989 - 2001 ASHP Foundation Psychiatric Drug Therapy Research Fellowship, 1988-93, 1995-96 ASHP Foundation Awards Program Selection Panel, 1998 ASHP Foundation Drug Therapy Research Award Selection Panel, 1999-2006 Astra Clinical Pharmacy Research Awards, 1998-2000 Cooperative Grants Program, U.S. Civilian Research and Development Foundation, 2003

Professional Meeting Submitted Papers

ASHP Midyear Clinical Meeting, 1982-84 American Association of Colleges of Pharmacy (AACP) Annual Meeting, 1987 American College of Clinical Pharmacy Annual Meeting (ACCP), 1987-92, 1995-2006 American College of Clinical Pharmacy Spring Practice and Research Forum, 1997-2005 International Congress on Clinical Pharmacy, 1999 National Head Injury Foundation Annual National Symposium, 1990-91 TEACHING EXPERIENCE Developed and served as director of ASHP accredited residency in Psychiatric Pharmacy Practice (in collaboration with Austin State Hospital, Texas Department of State Health Services, and Seton Health Network) until 2007. This is one of the oldest continuously operating, accredited psychiatric pharmacy residency programs in the country, and we 39 psychiatric pharmacy residents trained in the program under my leadership Developed post-Pharm.D. clinical sciences research fellowship in psychiatric pharmacotherapy (in collaboration with Austin State Hospital, TDMHMR). Eleven individuals completed psychiatric pharmacotherapy research fellowships in our program. Developed new collaborative arrangements for experiential teaching in multiple area health-systems, including: North Austin Medical Center, Austin State Hospital, Austin Veterans’ Affairs Clinic, Center for Clinical Research of the Austin Diagnostic Clinic, Healthcare Rehabilitation Center, Healthquest, Inc., Bluebonnet Trails MHMR Center, Olin Teague VA Medical Center, Scott and White Hospital and Clinics, Seton Health Netwrok, Radiant Research Inc., and Austin Medical Education Program. Developed new collaborative arrangements for multidisciplinary research with: Austin State Hospital, Center for Clinical Research of the Austin Diagnostic Clinic, Radiant Research, Inc.,


Page 51 August 2016

Healthcare Rehabilitation Center, TDMHMR, University of Texas Southwestern Medical Center at Dallas Department of Psychiatry, and University of Texas Health Sciences Center at San Antonio Department of Psychiatry. Chaired taskforce to develop recommendations for creation of College’s Honors Program. Member of taskforce to develop recommendations for College’s Ph.D. program in Pharmacotherapy. Member of taskforce to develop recommendations for College’s Option II M.S. program in Pharmacy Administration. Member of taskforce to develop recommendations for College’s Pharm.D./Ph.D. program. Consultant to develop curriculum and course content (and taught) for post-diploma B.S. degree program in pharmacy at College of Arts, Science, and Technology (currently University of Technology, Jamaica), Kingston, Jamaica. (Spent part of two summers consulting and teaching in their program.) Visiting professor to the Institute of Mental Health, Singapore, Singapore, January 2007. Developed, coordinated, and implemented a nationwide program to teach mental health organizations how to implement algorithm based disease management programs for care of individuals with severe mental disorders. Our complete program, funded by grants from the Robert Wood Johnson Foundation, and the Substance Abuse and Mental Health Services Administration, has been taught to mental health organizations in at least 16 different states. Several other states and a few other countries have adopted parts of our program. Developed and direct residency program in psychiatric pharmacy practice integrated with graduate education (MS or PhD) in mental health outcomes research. To date, I have supervised 1 PhD student and 5 MS students who have completed their degrees. Collaborated with The REACH Institute, NY, NY to develop and implement an intensive educational program utilizing behaviorally focused teaching methods to prepare primary clinicians to provide mental health care for children and adolescents. Conduct patient case discussions with Child & Adolescent Psychiatry Fellows, UT Dell Medical School and Seton Family of Hospitals

Courses Developed: Clinical clerkship in psychiatric pharmacy practice at Austin State Hospital Clinical clerkship in psychiatric pharmacy practice at Healthcare Rehabilitation Center Elective clinical clerkships in geriatric psychiatric pharmacy practice and child/adolescent

psychiatric pharmacy practice at Austin State Hospital Disease Processes and Pharmacotherapeutics (PHR 566L) Pharmacy Practice Laboratory II (PHR 266T) Advanced Pharmacy Practice (PHR 281T)


Page 52 August 2016

Biomedical Ethics (PHR 231) Drugs in Our Society for upper division non-pharmacy majors (PHR 350K) Clinical Pharmacology and Therapeutics for Advanced Nurse Practitioners (PHR 395C) Clinical Psychopharmacology and Therapeutics Course for Psychiatry Residents at Austin

State Hospital Pathophysiology and Pharmacotherapy of Psychiatric Disorders (PHR 490QA and 490QB)

– Graduate Course Methods in Clinical Psychopharmacology and Mental Health Outcomes Research (PHR

381M) – Graduate Course Clinical Psychopharmacology & Therapeutics Course for Psychiatry Residents at UT

Southwestern Medical Center – Austin, Seton Family of Hospitals Clinical Psychopharmacology & Therapeutics Course for Child & Adolescent Psychiatry

Residents at UT Southwestern Medical Center – Austin, Seton Family of Hospitals Revamped course in Current Healthcare Topics with Dr. Kenneth Lawson

Taught in multiple other courses for B.S. Pharmacy and Pharm.D. students INVITED PAPERS AND PRESENTATIONS (Exclusive of poster presentations if listed under abstracts.) International, National and Regional

Dr. Crismon has authored over 110 different presentations before international, national and regional professional, academic, or scientific groups, including the following since January 1, 1996:

Pharmacoeconomics of depression. Central Neuropsychiatric Association 1996 Fall Scientific Program, Scottsdale, Arizona, November 1996. Monitoring outcomes for recently released antipsychotic medications in a state hospital. 31st Annual ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December 1996. Effects of naltrexone on self injurious behavior and neurochemical markers associated with personality disorders of the flamboyant subtype. 31st Annual ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December 1996. Life after board certification. Annual Psychiatric Pharmacy Luncheon. 31st Annual ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December 1996. Dementia: the economic impact. Symposium entitled: Managing Psychiatric Illnesses in the Demented Elderly Patient: Economic and Therapeutic Considerations. 31st Annual ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December 1996.

Administrative considerations in implementing algorithms. Workshop entitled: Development and Evaluation of Medication Treatment Algorithms. 37th Annual NIMH New Clinical Drug Evaluation Meeting, Boca Raton, Florida, May 1997.


Page 53 August 2016

Development and implementation of treatment algorithms. Evaluating Behavioral Health Services Reform: Myths and Realities. 39th Annual Southern Regional Conference on Mental Health Statistics, New Orleans, Louisiana, September 1997. Insights, mechanisms, and treatments in Alzheimer’s disease. Symposium entitled: Advances in Parkinson’s disease & Alzheimer’s disease. 32nd Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1997. Evaluation of educational materials in an acute care psychiatric population. 32nd Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1997. Nefazodone augmentation in schizophrenia. 32nd Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1997. Successful strategies for gaining prescribing privileges for pharmacists. Opening General Session entitled: Pursuing Prescribing Authority for Pharmacists. 1998 ACCP Spring Practice and Research Forum, Palm Springs, California, April 1998. Developing and implementing algorithms. Symposium entitled: Pharmacotherapeutic Guidelines and Algorithms in the Treatment of Psychiatric Disorders. 1st International Meeting of the College of Psychiatric and Neurologic Pharmacists, Orlando, Florida, April 1998. The use of algorithms in schizophrenia. Symposium entitled: Pharmacotherapeutic Guidelines and Algorithms in the Treatment of Psychiatric Disorders. 1st International Meeting of the College of Psychiatric and Neurologic Pharmacists, Orlando, Florida, April 1998. Clinical use of rating scales for patient care. Clinical Pearls Interactive Session. 1st International Meeting of the College of Psychiatric and Neurologic Pharmacists, Orlando, Florida, April 1998. The role of the pharmacist in optimizing clinical outcomes. Symposium entitled: Recognizing Goals of Therapy in Alzheimer’s Disease. ASHP Annual Meeting ‘98, Baltimore, MD, June 1998. Garnering human and financial resources to enact collaborative authority. Symposium entitled: Collaborative Drug Therapy Management. ACCP 1998 Annual Meeting, Cincinnati, Ohio, November 1998. Weight gain associated with atypical antipsychotics. 33rd Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1998. Effects of medication regimen reviews on patient outcomes of chronically hospitalized psychiatric patients. 33rd Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1998. The role of the pharmacist in optimizing clinical outcomes. Symposium entitled: Understanding Alzheimer’s disease: Clinical evaluation & advances in treatment. 33rd Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1998.


Page 54 August 2016

Treatment algorithms and practice guidelines. 2nd Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists, Lake Tahoe, Nevada, March 1999. Advances in psychopharmacology. National Association for Home Care National Clinical Home Care Conference and Home Healthcare Nurses Association Annual Convention, Dallas, Texas, May 1999. Issues in guideline development. Symposium entitled: Texas Medication Algorithm Project: update. American Psychiatric Association’s 51st Institute on Psychiatric Services, New Orleans, Louisiana, October 1999. Pathophysiology and treatment of depression. Pharmacia & UpJohn National Managed Care Advisory Board Meeting. Scottsdale, Arizona, November 1999. Considerations in adopting and implementing treatment guidelines for the mentally ill. Symposium entitled: Use of treatment guidelines to improve outcomes in the mentally ill. 34th Annual ASHP Midyear Clinical Meeting, Orlando, Florida, December 1999. Translating evidence into practice: dissemination, implementation, evaluation. Third Annual Veterans’ Affairs National QUERI Meeting, Reston, Virginia, February 2000. Texas Medication Algorithm Project. American Drug Utilization Review Symposium – ADURS 2000, Austin, Texas, February 2000. Economic and patient considerations in treatment of depression. Vestra National Speakers Bureau Meeting, Miami Beach, Florida, March 2000. Texas Medication Algorithm Project: Strategies for Implementing Medication Algorithms. 5th Annual Conference of the National Association of County Behavioral Health Directors. Charlotte, North Carolina, July 2000. Building shareholder consensus for practice guideline implementation in public sector systems. 12th Annual Behavioral Healthcare Tomorrow Conference, Washington, DC, September 2000. Developing and implementing treatment guidelines for depression. Symposium entitled: Depressive Illness: Managing Comorbidity and Treatment Algorithms, Academy of Managed Care Pharmacy 2000 Education Conference, San Diego, California, October 2000. Treatment algorithms for management of schizophrenia. Symposium entitled: The Changing Face of Antipsychotic Therapy: Real-World Considerations. 35th Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 2000. Pharmacotherapy of psychosis and behavioral problems in dementia. Exhibitor’s Theatre entitled: Clinical Advances in Alzheimer’s Disease. 35th Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 2000.


Page 55 August 2016

Treatment algorithms for the management of depressive illness. Symposium entitled: Management of Depression: Current Practice and Future Directions. 35th Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 2000. TMAP study methodology. Panel Session entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. American College of Neuropsychopharmacology 39th Annual Meeting, San Juan, Puerto Rico, December 2000. The Texas Medication Algorithm Project (TMAP): Rationale and design. Symposium entitled: The Texas Medication Algorithm Project (TMAP): Results of a 3 Year Study. American Psychiatric Association Annual Meeting, New Orleans, LA, May 2001. Children’s Medication Algorithm Project. Pediatric Psychopharmacology Workgroup. American Public Human Services Association, Washington, DC, July 2001. New antipsychotics: how effective, at what cost? 13th Annual Behavioral Healthcare Tomorrow Conference, Washington, DC, October 2001. Overview of algorithms: consensus to CMAP. Symposium entitled: Lessons Learned from the Children’s Medication Algorithm Project. 48th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Honolulu, Hawaii, October 2001. Considerations in the treatment of depression in the elderly. Symposium entitled: Implications of long-term therapy in the treatment of depression. American Society of Consultant Pharmacists’ 32nd Annual Meeting, Chicago, Illinois, November 2001. Utilizing systems of care to improve outcomes among the mentally ill. Judith K. Saklad Memorial Lecture, College of Psychiatric and Neurologic Pharmacists 5th Annual Meeting, Seattle, WA, April 2002. TMAP: Utilizing systems of care to improve outcomes among the mentally ill. PRO Workshop Spring 2002 Series. Substance Abuse and Mental Health Services Administration and Centers for Medicare and Medicaid Services, Baltimore, MD, May 2002. Utilizing database analyses to optimize decision-making. Medicaid Mental Health Advisory Board Meeting. Janssen Pharmaceutica, Phoenix, AZ, October 2002. Issues in treatment adherence for patients with schizophrenia. Symposium entitled: Thinking Outside the Box: A Long-term View of Antipsychotic Therapy. 2002 Annual Meeting American College of Clinical Pharmacy, Albuquerque, NM, October 2002. Lessons learned from the Texas Medication Algorithm Project (TMAP). Symposium entitled: The Science Behind Developing, Disseminating, and Implementing Practice Guidelines. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 2002. Appropriate management of mood disorders: rapidly evolving treatment guidelines. Symposium entitled: Unmet Needs in the Treatment of Mood Disorders: Role of Atypical Antipsychotics.


Page 56 August 2016

College of Psychiatric and Neurologic Pharmacists 6th Annual Meeting, Charleston, SC, May 2003. Utilization patterns of antipsychotics agents within the Texas Department of Criminal Justice inmate population. U.S. Psychiatric and Mental Health Congress Annual Meeting, Orlando, FL, November 7, 2003. Utilizing organizational change management to implement clinical guidelines. Workshop entitled: Central Nervous System PRN: Around the World – Implementing Clinical Guidelines into Practice. 2nd ACCP –ESCP International Congress on Clinical Pharmacy, Paris, France, April 2004. Medication algorithms and clinical evidence in ADHD and mood disorders in children. National Algorithm Conference, Orlando, FL, May 2004. Utilizing algorithms and systems of care to improve mental health outcomes. Plenary session entitled: What do we mean by “Evidence-Based Practices?”: A look at approaches in medication management. National Mental Health Association Healthcare Policy Conference, Alexandria, VA, October 2004.

Cost-Outcome for Patients with Bipolar Disorder in the Texas Medication Algorithm Project (TMAP). Symposium entitled: Controlled Trials of Service Delivery Models for Bipolar Disorder, 18th NIMH Research Conference on Mental Health Services Research MHSR 2005, Bethesda, MD, July 2005. The burden of mental disorders on care: implications for MCOs. Symposium entitled: The Burden of Mental Disorders on Care: Implications for MCOs in 2006 and Beyond. 18th Annual Meeting of the Academy of Managed Care Pharmacy, Seattle, WA, April 2006. Clinical and cost outcomes in the Texas Medication Algorithm Project. Symposium entitled: The Burden of Mental Disorders on Care: Implications for MCOs in 2006 and Beyond. 18th Annual Meeting of the Academy of Managed Care Pharmacy, Seattle, WA, April 2006. Management of treatment resistant depression. 9th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Baltimore, MD, April 2006. Understanding ADHD for children: HEDIS and beyond. Web based education program sponsored by the National Committee for Quality Assurance. URL: http://web.ncqa.org/tabid/178/Default.aspx, October 2006. Use of vagal nerve stimulation in refractory depression. Central Nervous System Practice and Research Network Meeting. American College of Clinical Pharmacy 2006 Annual Meeting, St. Louis, MO, October 2006. CMAP Algorithms: Evidence based pharmacotherapy for mental disorders among youth. American Drug Utilization Review Society Annual Symposium: ADURS 2007, Dallas, TX, February 2007.


Page 57 August 2016

ADHD: Clinical tools for improving patient outcomes. Symposium entitled: Managing ADHD in a fast-paced world. 19th Annual Meeting of the Academy of Managed Care Pharmacy, San Diego, CA, April 2007. Pharmacotherapy practices. Consensus Meeting on Developing Guidelines for Best Practices on Mental Health Approaches in Child Welfare. The REACH Institute and the Anne E. Casey Foundation, Washington, DC, October 2007. TMAP: Challenges with implementation in the real world. Conference entitled: Connecting Science and Service: A Planning Meeting for the Southern Region. National Institute of Mental Health. Nashville, TN, November 2007. Management of aggression in children and adolescents. 14th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists. Phoenix, AZ, May 2011. Interim report: Council of Deans Taskforce on Healthcare Reform’s Impact on Pharmacy Education. AACP Interim Meeting, San Diego, CA, February 2012 Pharmacist entry level patient care competencies in a transformed healthcare market. AACP COD Special Educational Session: Pharmacy Education in a Transformed Health Market. AACP Annual Meeting, Kissimmee, FL, July 2012. Psychotropic medication use in foster children and adolescents. Royal College of Surgeons in Ireland and the Pharmaceutical Society of Ireland. Dublin, Ireland, March 2013. Developing a culture of faculty engagement. Council of Deans Networking Session I: Effective utilization of administrative tools. AACP Annual Meeting, Chicago, IL, July 2013. Perspectives on the future of pharmacy practice and pharmacy education. Dubai International Pharmaceuticals & Technologies Conference (DUPHAT), Dubai, UAE, March 2015. Improving the use of psychotropic medication in children and youth. Dubai International Pharmaceuticals & Technologies Conference (DUPHAT), Dubai, UAE, March 2015. Medication therapy management: Perspectives from the Texas Pharmacy Congress and from academia. AHRQ Health Care Innovations Exchange – Integrating the pharmacist into the interdisciplinary MTM team: an added value in achieving improved medication access, adherence, management, and outcomes. Houston, TX, September 1015. Pharmacy residency programs and specialization in the USA. Session titled, Specialization in pharmacy – professional recognition in the European Union. FIP World Congress of Pharmacy & Pharmaceutical Sciences, Dusseldorf, Germany, October 2015. Building a functional, productive, and successful research program at the college level – panel discussion. AACP Academic Research Fellows Program, Houston, TX, January 2016.

State


Page 58 August 2016

Dr. Crismon has delivered over 166 different presentations before state professional, academic, or scientific groups, including the following since January 1996:

Psychiatric pharmacy specialty. 1996 Feurt Symposium: Certification, Specialization and Licensure. The University of Tennessee, Memphis, Tennessee, January 1996. New perspectives on drug interactions. Texas Academy of Physician Assistants 21st Annual Primary Care Conference, Dallas, Texas, March 1996. Pharmacoeconomics of depression. TXMHMR Consensus Conference on Treatment of Depression, Galveston, Texas, July 1996. Update on treatment of depression. Indiana Pharmacists Association -- Indiana Society of Health-System Pharmacists 1996 Joint Meeting, French Lick, Indiana, August 1996. Drug induced dyskinesias and tics. TXMHMR ComNET CME Series, Austin, Texas, August 1996. Pharmacoeconomics of bipolar disorder. TXMHMR Conference on Schizophrenia and Bipolar Disorder Algorithms, Dallas, Texas, September 1996. Development and implementation of medication algorithms. Symposium entitled: The pharmacist and disease management: an overview. Texas Society of Health-System Pharmacists 49th Annual Seminar, Austin, Texas, April 1997. Rational approaches to psychotropic polypharmacotherapy. TXMHMR ComNET CME Series, Austin, Texas, April 1997. The Texas Medication Algorithm Project. 1997 Texas Alliance for the Mentally Ill Convention, League City, Texas, September 1997. Advances in the pharmacotherapy of Alzheimer’s disease. 1997 TXMHMR Physicians’ Conference, Austin, Texas, September 1997. Ethics of conducting research in psychiatric patients. Ninth Annual Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 1997. Texas Medication Algorithm Project, Phases 1 & 2. Texas Medication Algorithm Project Benefactors’ Meeting, Dallas, Texas, October 1997. Alzheimer’s disease: New treatments and preventive strategies. Texas Society of Health-System Pharmacists 50th Annual Seminar, Houston, Texas, April 1998. Rationale for and principles of medication algorithms. Children’s Medication Algorithm Project (CMAP) Consensus Conference on Major Depressive Disorder, Dallas, Texas, June 1998.


Page 59 August 2016

Treatment algorithm development process. Children’s Medication Algorithm Project (CMAP) Consensus Conference on Attention Deficit Hyperactivity Disorder, Austin, Texas, July 1998. Principles of developing medication algorithms: Children’s Medication Algorithm Project. The Texas Alliance for the Mentally Ill 14th Annual Conference, San Antonio, Texas, September 1998. Therapeutics controversies: What is first line treatment of schizophrenia? Tenth Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 1998. Use of psychotropic medications in hepatic failure, renal insufficiency, and cardiac disease. TMAP Interim Physician and Clinical Coordinator Conference, Galveston, Texas, November 1998. The Texas Algorithm Project: Development, implementation, and evaluation of treatment algorithms. New Mexico Pharmacotherapy Initiative Consensus Conference, Santa Fe, New Mexico, January 1999. Advances in treatment of psychosis. TXMHMR ComNET CME Series, Austin, Texas, January 1999. Advances in the pharmacotherapy of major depressive disorder. TXMHMR ComNET CME Series, Austin, Texas, May 1999. Advances in the pharmacotherapy of schizophrenia. TXMHMR Annual Physicians Conference, Austin, Texas, August 1999. Treatment algorithms for schizophrenia: integrating them into your practice. 11th Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 1999. Use of psychotropics in patients with systemic organ dysfunction. Schizophrenia Algorithm Implementation Symposium, Falls Church, Virginia, April 2000. Pharmacotherapeutic update for depression algorithms. Correctional Mental Health Care in the New Millennium, California Department of Corrections, Sacramento, California, April 2000. Advances in the pharmacotherapy of depression. Pharmacology/Pharmacotherapeutics Update. The University of Texas College of Pharmacy, Austin, Texas, May 2000. Recent advances in antidepressant drug therapies. 12th Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, November 2000. Utilization of rating scales in clinical practice. 12th Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, November 2000.


Page 60 August 2016

Changing the system: how one state is succeeding. Symposium entitled: The Emerging Public Sector Dilemma: Affording Quality Mental Health Care for Schizophrenia. Columbus, Ohio, March 2000; Orlando, Florida, April 2000; Jefferson City, Missouri, June 2000; Portland, Oregon, November 2000; Oklahoma City, Oklahoma, November 2000. Enhancing systems of care to improve patient outcomes. Robert G. Leonard Memorial Lecture. Texas Society of Health-System Pharmacists Annual Seminar, Austin, Texas, April 2001. The Texas Medication Algorithm Project: Results of a 3-year study. TDMHMR Annual Physicians’ Conference, Austin, Texas, April 2001. Update on Antipsychotics. TDMHMR Annual Physicians’ Conference, Austin, Texas, April 2001. Depression education – experiences from the Texas Medication Algorithm Project. 5th Annual – The Practical Use of Psychiatric Medications. Rocky Mountain College Physician Assistant Program and The University of Montana School of Pharmacy and Allied Health Sciences, Billings, MT, April 2001. Applying treatment algorithms for depression. 13th Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 2001. Implementing treatment algorithms and quality improvement. Tennessee Department of Mental Health, Nashville, Tennessee, December 2001. Texas implementation of medication algorithms. Robert Wood Johnson Foundation Synergy Meeting, San Antonio, Texas, May 2002. Developing evidence based, treatment algorithms. Consensus Conference to Develop Guidelines for the Prevention, Diagnosis, and Treatment of Osteoporosis in the Mentally Retarded. Texas Department of Mental Health and Mental Retardation, Austin, TX, June 2002. TMAP: Utilizing systems of care to improve outcomes among the severely mentally ill. Governor’s Conference: Creating a functional marketplace for prescription drugs. Portland, OR, October 2002. Using algorithms to improve outcomes among the mentally ill. Symposium entitled: Use of Algorithms and Treatment Protocols, Annual New Jersey Drug Utilization Review Board All Day Seminar. New Jersey Pharmacists Association, Iselin, NJ, November 2002. Implementing algorithms to improve outcomes among the mentally ill. Pennsylvania Medication Algorithm Project Train the Trainers Symposium, Harrisburg, PA, December 2002. Utilization factors that influence medication costs. Conference on Pharmaceutical Costs, Texas Department of Mental Health and Mental Retardation, Austin, TX, February 2003. Patient and family education: a solution for partial adherence. New Jersey Association of Mental Health Agencies, Princeton, NJ, April 2003.


Page 61 August 2016

TMAP: Utilizing systems of care to improve outcomes among the severely mentally ill. Keynote address. Alabama Department of Mental Health & Mental Retardation Third Psychiatric Institute, Birmingham, AL, July 2003. TMAP: Implementing algorithms in public mental health systems. Alabama Department of Mental Health & Mental Retardation Third Psychiatric Institute, Birmingham, AL, July 2003. Pharmacotherapy of common child and adolescent mental disorders. 51st Annual Postgraduate Pharmacy Seminar, The University of Texas at Austin, Austin, TX, September 2003. Evidence based practices for improving care for mood disorders. 15th Annual Psychiatric Pharmacy Update, The University of Texas at Austin, Austin, TX, October 2003. Medication algorithms and guidelines. Behavioral Health Care Update: Best Practices, Best Outcomes. University Behavioral Healthcare, University of Medicine & Dentistry of New Jersey, Edison, NJ, October 2003. Panel member, Mental health, quality measurement & improvement initiatives. State of Our Health: Measuring Quality and Achieving Success, A Texas Leadership Forum on Healthcare Quality Measurement and Improvement, Austin, TX, December 2003. Children’s Medication Algorithm Project. Texas Adolescent Health Meeting, Texas Department of Health, Austin, TX, April 2004. Medically related adverse effects of medications for bipolar disorder, Texas Consensus Conference to Revise and Update the Bipolar Disorder Treatment Algorithms, Dallas, TX, May 2004. Texas Medication Algorithm Project and outcomes assessment. Texas Hospital Association Annual Psychiatric Services Conference, San Antonio, TX, July 2004. Rationale and principles for algorithm development. Attention Deficit Hyperactivity Disorder Expert Consensus Conference, Texas Department of State Health Services, Dallas, TX, September 2004. Alpha agonists in the treatment of primary ADHD Attention Deficit Hyperactivity Disorder Expert Consensus Conference, Texas Department of State Health Services, Dallas, TX, September 2004. Treatment recommendations for aggression among youth. 16th Annual University of Texas Psychiatric Pharmacotherapy Update, Austin, TX, October 2004. Rationale and Principles of Medication Algorithms. Expert Consensus Conference on Treatment of Depression in Children and Adolescents, Texas Department of State Health Services, Dallas, TX, January 2005.


Page 62 August 2016

Pharmacodynamics of atypical antipsychotics. Psychopharmacology Workshop: Texas Mental Retardation State Schools and Centers Physicians, Austin, TX, May 2005. Treatment of psychiatric and behavioral problems in individuals with mental retardation: Consensus guideline recommendations. Psychopharmacology Workshop: Texas Mental Retardation State Schools and Centers Physicians, Austin, TX, May 2005. Development, implementation, and evaluation of the TMAP algorithms for major depressive disorder. Goldman Algorithm Conference for the Development of an Algorithm to Treat Depression in Patients with Multiple Sclerosis. New York Chapter of the National Multiple Sclerosis Society, New York, NY, July 2005. Treatment of acute mania. 17th Annual University of Texas Psychiatric Pharmacotherapy Update, Austin, TX, September 2005. Rational antipsychotic polypharmacy – what is it? 17th Annual University of Texas Psychiatric Pharmacotherapy Update, Austin, TX, September 2005. Psychotropic medication use for foster children. 16th Annual Texas CASA Conference, Plano, TX, October 2005. Management of treatment resistant depression. 10th Annual Conference on the Practical Use of Psychiatric Medication. Northwest Research and Education Institute, Billings, MT, April 2006. Professionalism of pharmacy students. Preceptor Orientation and Training Conference, University of Texas College of Pharmacy, Salado, TX, August 2006. Update on attention deficit hyperactivity disorder in children and adolescents. 54th Annual University of Texas Pharmacy Practice Seminar, Austin, Texas, September 2006. Development and revision of the TMAP algorithms. Texas Consensus Conference for the Revision of the Algorithms for Major Depressive Disorder, Dallas, Texas, September 2006. Networking session on pharmacy careers. Alcalde XXI, Southwest Leadership Conference, San Antonio, TX, April 2007.

Professionalism, Texas Pharmacists Association Annual Meeting, Grapevine, TX, July 2007.

Pharmacy education in the 21st century. West Texas Pharmacy Association, San Angelo, TX, April 2008. Pharmacotherapy of Attention Deficit Hyperactive Disorder, 20th Annual Psychiatric Pharmacotherapy Update, The University of Texas College of Pharmacy, Austin, X, September 2008. Pharmacy Education in the 21st Century, Texas Federation of Drug Stores Annual Meeting, Bastrop, TX, October 2008.


Page 63 August 2016

Treating ADHD: Getting the most out of medication. NEI Clinical Update: ADHD, Seattle, WA, October 2009.

The future of pharmacy. West Texas Pharmaceutical Association, Fredericksburg, TX, February 2011. Pharmacist entry level patient care competencies in a transformed healthcare market, West Texas Pharmaceutical Association, Midland, TX, April 2012

Psychopharmacology for children in substitute care. Texas CASA Webinar, Austin, TX, May 2012 Pharmacy practice competencies in a transformed healthcare market. The University of Texas Pharmacy Practice Seminar, Austin, TX, September 2012.

Prescribing Parameters for use of Psychotropic Medications in Children and Adolescents. 92nd Annual Meeting of the West Texas Pharmacy Association, El Paso, TX, April 2013.

Psychotropic medication utilization parameters for foster children and youth. West Texas Pharmacy Association Annual Meeting, Lubbock, TX, April 2014. Pediatric psychopharmacology update. 26th Annual University of Texas Psychiatric Pharmacotherapy Update, Austin, TX, October 2014. The state of healthcare in Texas: What is the future of Pharmacy? Texas Pharmacy Association Leadership Symposium, Austin, TX, April 2015.

Update on the use of psychotropic medications in children and youth. West Texas Pharmacy Association Annual Meeting, Abilene, TX, April 2015. The future of pharmacy practice and pharmacy education. West Texas Pharmacy Association Annual Meeting, Abilene, TX, April 2015. Current Topics Regarding the Use of Psychotropic Medication in Children and Youth. New Mexico Pharmacists Association 2016 Mid-Winter Meeting, Albuquerque, NM, January 2016. Perspectives on the future of pharmacy practice and pharmacy education. West Texas Pharmacy Association Annual Meeting, San Antonio, TX, April 2016. Deans’ Townhall. TSHP Annual Seminar. April 2007; 2008; 2010; 2012; 2013; 2014; 2015; 2016.

Local

Dr. Crismon has delivered over 190 different presentations before local professional associations, organized health care settings, or universities, including the following since January 1996:


Page 64 August 2016

Update on recently released antidepressants. Austin Area Society of Health-System Pharmacists Spring Seminar, Austin, Texas, March 1996. Advances in the pathophysiology and treatment of Alzheimer’s disease. Internal Medicine Grand Rounds, Central Texas Medical Foundation, Brackenridge Hospital, Austin, Texas, August 1996. New perspectives on drug interactions. Lubbock Area Society of Health-System Pharmacists Annual Seminar, Lubbock, Texas, March 1997. Texas Medication Algorithm Project. Department of Psychiatry Grand Rounds, University of Texas Health Science Center at San Antonio, San Antonio, Texas, January 1998. Development, implementation, and evaluation of medication algorithms. Austin Area Society of Hospital Pharmacists, Austin, Texas, February 1998. Texas Medication Algorithm Project. Dean’s Advisory Council Meeting, College of Pharmacy, The University of Texas, Austin, Texas, March 1998. Texas Medication Algorithm Project. Faculty Retreat, College of Pharmacy, The University of Texas, Lakeway, Texas, May 1998. Considerations in using treatment algorithms in the public mental health sector. Symposium entitled: Implementing Medication Algorithms in the Public Mental Health Sector. Las Vegas Medical Center, Las Vegas, New Mexico, June 1998. The use of algorithms in schizophrenia. Symposium entitled: Implementing Medication Algorithms in the Public Mental Health Sector. Las Vegas Medical Center, Las Vegas, New Mexico, June 1998. Health care indicators for quality improvement. The Practical Outcomes Researcher Workshop. San Antonio, Texas, October 1998. Advances in the pharmacotherapy of depression. Austin, Texas, September 1998. Metroplex Hospital, Kileen, Texas, November 1998. Texas Medication Algorithm Project. Department of Psychiatry Grand Rounds, The University of Texas Medical Branch, Galveston, Texas, March 1999. Psychotropic use in patients with co-morbid medical disorders. Kerrville State Hospital, Kerrville, Texas, April 1999. Gulf Coast and Riceland MHMR Centers, Houston, TX, July 1999. Austin State Hospital, Austin, TX, July 1999. Central Texas MHMR Centers, Waco, Texas, August 1999 Advances in the pharmacotherapy of Alzheimer’s disease. ACCP Regional Chapter, Dallas, Texas, April 1999.


Page 65 August 2016

Advances in the pharmacotherapy of Alzheimer’s disease. Kaiser Permanente, Denver, Colorado, August 1999. Implementing medication algorithms: an overview. Meeting of the Multi-state Mental Health Algorithm Research Initiative, Dallas, Texas, August 1999. Texas Medication Algorithm Project. Advocacy, Inc., Austin, Texas, October 1999. Updated issues in the diagnosis and management of depression. Metroplex Society of Health-System Pharmacists Annual Fall Seminar, Dallas, Texas, October 1999. Use of antidepressants in patients with systemic organ dysfunction. Schizophrenia Algorithm Implementation Symposium. Washington, DC Commission on Mental Health, Washington, D.C., April 2000. Uniform documentation of patient outcomes in schizophrenia. Implementation of Schizophrenia Algorithm Symposium, Cincinnati, Ohio, May 2000. Pharmacoeconomics/Outcomes: Maximizing resources for optimal care. NorthSTAR 1st Annual Psychiatric Update. The University of Texas Southwestern Medical Center and ValueOptions NorthSTAR, Dallas, Texas, January 2001. Treatment algorithms for the management of schizophrenia. Salt Lake City, Utah, March 2001. Implementing treatment algorithms. Utah State Hospital, Provo, Utah, March 2001. Improving mental health outcomes through guidelines and quality improvement. Colorado State Mental Health and Medicaid. Denver, CO, April 2001. Optimizing performance and accountability. Symposium on Mental Health Care in the New Millennium. Phoenix, AZ, April 2001; Tampa FL, April 2001; Buffalo, NY, April 2001; Madison, WI, May 2001; Nashville, TN, June 2001; Richmond VA, June 2001. Developing and implementing treatment algorithms for schizophrenia. Magellan Behavioral Health Corporate Headquarters, Columbia, MD, July 2001. Psychopharmacologic and clinical issues in antipsychotic drug use. North Texas State Hospital, Wichita Falls, TX, July 2001. Psychopharmacologic, clinical, and economic issues in antipsychotic drug use. Heart of Texas MHMR Center, Waco, TX, August 2001; and Life Management Center, El Paso, TX, August 2001. Quality management issues in implementing treatment algorithms. Rusk State Hospital, Rusk, TX, August 2001; and Austin State Hospital, Austin, TX, August 2001.


Page 66 August 2016

TMAP: enhancing systems of care to improve patient outcomes. Washington DC Department of Mental Health, Washington, DC, August 2001. TMAP algorithm for schizophrenia. Nevada Department of Mental Health, Las Vegas, NV, September 2001; Washington DC Department of Mental Health, Washington, DC, November 2001. Tailoring the treatment of depression to the complex patient: using the geriatric patient as a model. Symposium entitled: Tailoring the treatment of depression to the complex patient. Dallas, TX, October 2001; Houston, TX, November 2001. Overview of psychotropic medication drug interactions. Washington DC Department of Mental Health, Washington, DC, November 2001; Pittsburgh, PA, November 2001; Community Partnership of Southern Arizona, Tucson, AZ, December 2001.

Implementing treatment algorithms and quality improvement. Multistate Algorithm Implementation Program. Nevada Department of Mental Health, Las Vegas, NV, September 2001; Kentucky Department of Mental Health, Louisville, KY, October 2001; Mayview State Hospital, Pittsburgh, PA, November 2001; Community Partnership of Southern Arizona & University of Arizona, Tucson, Arizona, December 2001; San Diego Department of Mental Health, San Diego, CA, November 2002. TMAP: A study of algorithm driven treatment for serious mental illness. College of Pharmacy, The University of Texas, Austin, TX, January 2002. TMAP: Utilizing systems of care to improve outcomes among the severely mentally ill. Philip C and Ethel F Ashby Endowed Lecture Series, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, February 2002. Considerations in guideline development. Consensus conference to develop smoking cessation strategies for minority populations. Texas Tech University Health Sciences Center Department of Neuropsychiatry, Lubbock, Texas, April 2002. TIMA algorithms for bipolar mood disorder. Community Partnership of Southern Arizona and the University of Arizona, Tucson, AZ, October 2002. Adverse effects, drug interactions, & antipsychotic choice. Multistate Algorithm Implementation Program. San Diego Department of Mental Health, San Diego, CA, November 2002. TIMA algorithms for psychotic depression. Community Partnership of Southern Arizona and the University of Arizona, Tucson, AZ, December 2002. Implementing algorithms to improve outcomes among the mentally ill. Kaiser Permanente, Denver, CO, March 2003; South Carolina Department of Mental Health and Medical University of South Carolina, Charleston, SC, March 2003.


Page 67 August 2016

Patient education: critical component of TMAP. South Carolina Department of Mental Health and Medical University of South Carolina, Charleston, SC, March 2003. Mock IRB Panel. Symposium entitled, A Privilege Not a Right – Conference on Human Subjects Research Protection. The University of Texas, Austin, TX, May 2003. Pharmacoeconomics of schizophrenia. North Shore Behavioral Health Network, Cleveland, OH, April 2003; Breckville Veterans’ Affairs Medical Center, Cleveland, OH, April 2003; Department of Psychiatry Grand Rounds, Texas A&M University Health Science Center, Temple, TX, June 2003. TMAP outcomes and costs. TDMHMR Benefit Design Pilot Sites Management Teams, July 2003, Austin, TX; Tarrant County MHMR Center, Ft. Worth, TX, September 2003; TDMHMR Community Mental Health Advisory Committee, Austin, TX, August 2003; TDMHMR Board Meeting, Austin, TX, October 2003; Panhandle MHMR Center, November 2003; Tarrant County MHMR Center, Ft. Worth, TX, November 2003; Train-the-Trainers Seminar, Houston, TX, May 2004.

Development of a research and education program in mental health outcomes. Dean’s Advisory Council Meeting, The University of Texas College of Pharmacy, Austin, TX, March 2004. Key issues in consideration for program design, value to states and community mental health centers. Schizophrenia Quality Improvement Advisory Meeting. Applied Health Outcomes and Janssen Pharmaceutica, Tampa, FL, May 2004. Introduction to the TMAP/TIMA Algorithms. Train-the-Trainer Seminars, TDMHMR, Houston, TX, May 2004; San Antonio, TX, June 2004; Ft. Worth, TX, July 2004. Using brief rating scales to enhance clinical care. Train-the-Trainer Seminars, TDMHMR, Houston, TX, May 2004; San Antonio, TX, June 2004; Ft. Worth, TX, July 2004. TMAP: Utilizing algorithms and systems of care to improve mental health outcomes. Cal-MAP Training Symposium. Humboldt County Department of Mental Health. Eureka, CA, July 2004. Faculty issues: How to guide your students through the IRB. Symposium entitled, Human Subjects Research in Social & Behavioral Sciences: A Paradigm Shift? The University of Texas at Austin, Austin, TX, September 2004. An overview of the development, implementation, and evaluation of TMAP. Mendota Mental Health Institute, Madison, WI, July 2005 Updated CMAP algorithm for ADHD. Gunderson Lutheran Medical Center, LaCrosse, WI, July 2005. Applying the results of the CATIE trial to clinical care. Medical Staff, MHMRA of Harris County, Houston, TX, October 2005.


Page 68 August 2016

Use of a Markov model to predict long-term clinical and economic outcomes in treatment-resistant depression, Cyberonics, Inc., Houston, TX, November 2005. Introduction to the TMAP algorithms; The TMAP schizophrenia algorithm; and Introduction to clinical rating scales. Tennessee Algorithm Implementation Training Symposium, Western Mental Health Institute, Bolivar, TN, December 2005. Professionalism. Preceptor Conference Training, University of Texas College of Pharmacy, Austin, TX, January 2006.

Development of the academic health sciences in Austin, Dean’s Foundation Advisory Committee, University of Texas College of Pharmacy, Austin, TX, March 2006. Introduction to the TMAP algorithms; The TMAP schizophrenia algorithm; and Introduction to clinical rating scales. TMAP Implementation Training Symposium, Berriere Mental Health Authority, St. Joseph, MI, March 2006. Introduction to the TMAP algorithms; The TMAP algorithms for Major Depressive Disorder; and Introduction to clinical rating scales. Symposium entitled: Algorithm Driven Disease Management for the Pharmacotherapy of Major Depressive Disorder, Jackson Evidence Based Partnership, Jackson, MI, June 2006. CMAP algorithms for ADHD and depression. Texas Adolescent Medicine Mental Health in Primary Care Initiative, Longview TX, July 2006; Gonzalez, TX, August, 2006; El Paso, TX, August 2006; San Antonio, October 2006. Ongoing development of interdisciplinary biomedical research at UT Austin. Dean’s Advisory Council Meeting, The University of Texas College of Pharmacy, Austin, TX, September 2006. Transitions and emerging issues, Dean’s Advisory Council Meeting, The University of Texas College of Pharmacy, Austin, TX, March 2007. A College in Transition, Faculty Retreat, The University of Texas College of Pharmacy, New Braunfels, TX, August 2007. Planning for new horizons, Dean’s Advisory Council Meeting, The University of Texas College of Pharmacy, Austin, TX, September 2007. Experiences with Implementing Treatment Guidelines, Department of Psychiatry Grand Rounds, Medical College of Georgia, Augusta, GA, March 2008 Faculty entrepreneurism. Department of Pharmacy Practice, University of Georgia College of Pharmacy, Augusta, GA, March 2008. Pharmacy education in the 21st Century, UTCOP – UTEP Cooperative Pharmacy Program Preceptor Training Conference, El Paso, TX, November 2008.


Page 69 August 2016

Pediatric psychopharmacology overview. Understanding the 2004 FDA Black Box Warning on antidepressant use in children and adolescents. Treating ADHD: Getting the most out of medications, part I. What you need to know about adverse effects of atypical antipsychotics. Assessment and Managing Mental health Problems in Children and Adolescents: A Mini-Fellowship for Primary Clinicians, The REACH Institute and the New York Office of Mental Health, Buffalo, NY, August 2010. Experiences with implementing treatment guidelines. Psychiatry Department Grand Rounds, Scott & White Hospital and Clinics and Texas A&M University Health Science Center, Temple, TX, January 2011. Health care transformation and a changing pharmacy environment. Rho Chi Lecture, Irma Rangel College of Pharmacy, Texas A&M University Health Science Center, Kingsville, TX, April 2011. Faculty development workshop. Irma Rangel College of Pharmacy, Texas A&M University Health Science Center, Kingsville, TX, April 2011. Facilitating research excellence. First Tennessee Chair of Excellence Distinguished Visiting Professor, College of Pharmacy, The University of Tennessee Health Sciences Center, Memphis, TN, April 2011. Psychopharmacology training for foster parents. Harker Heights, TX, June 2012.

Pharmacist entry level patient care competencies in a transformed healthcare market. The University of Texas College of Pharmacy Annual Preceptor Conference. Austin, TX, August 2012. Pharmacist practice competencies in a transformed healthcare market. The University of Texas College of Pharmacy Homecoming Tailgate Celebration, September 2012. Update on prescribing parameters for the use of psychotropic medication in children and youth. Rio Grande Pharmacists Association, McAllen, TX, November 2013. Rational use of psychotropic medication. Disability Rights Texas. Austin, TX, August 2015. Update on the use of psychotropic medication in youth. Austin Psychiatric Society, January 2016. Perspectives on the future of pharmacy practice and pharmacy education. Alpha Alpha of Rho Chi Lecture Award, School of Pharmacy and Health Professions, Creighton University Medical Center, Omaha, NE, February 2016.

SYMPOSIA AND SESSIONS CHAIRED, COORDINATED, OR MODERATED


Page 70 August 2016

Dr. Crismon has chaired, coordinated, or moderated 40 different symposia or sessions at professional/scientific meetings, including the following since January 2002: Coordinator and moderator, The Pharmacist and Disease Management: an Overview. Texas Society of Health-System Pharmacists 49th Annual Seminar, Austin, Texas, April 1997. Chairman, First Plenary Session. 1st International Meeting of the College of Psychiatric and Neurologic Pharmacists, Orlando, Florida, April 1998 Chairman, Symposium entitled: Pharmacotherapeutic Guidelines and Algorithms in the Treatment of Psychiatric Disorders. 1st International Meeting of the College of Psychiatric and Neurologic Pharmacists, Orlando, Florida, April 1998 Co-Chair, Children’s’ Medication Algorithm Project (CMAP) Consensus Conference on Major Depressive Disorder, Dallas, Texas, June 1998. Co-Chair, Children’s Medication Algorithm Project (CMAP) Consensus Conference on Attention Deficit Hyperactivity Disorder, Austin, Texas, July 1998. Moderator, Reimbursement for pharmacy services panel discussion. Tenth Annual Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 1998. Meeting Chair. Second Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists, Lake Tahoe, Nevada, March 1999.

Moderator, Managing Complications in the Patient with Dementia. 11th Annual Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 1999. Moderator, Managing Depression and Anxiety. 11th Annual Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 1999. Chairman, Symposium entitled: Use of treatment guidelines to improve outcomes in the mentally ill. 34th Annual ASHP Midyear Clinical Meeting, Orlando, Florida, December 1999. Moderator, Managing aggression in children and adolescents. 13th Psychiatric Pharmacy Update, The University of Texas College of Pharmacy, Austin, Texas, September 2001. Moderator, Consumer/advocate panel. Consensus Conference to Integrate Evidence-based Psychotherapy with Evidence-based Pharmacotherapy for Major Depressive Disorder. University of Texas Southwestern Medical Center and TDMHMR, Dallas, TX, January 2002. Co-chair: Consensus Conference Panel to Develop Guidelines to Motivate Mexican-Americans to Participate in Smoking Cessation Programs. Texas Tech University Health Sciences Center Department of Neuropsychiatry, Lubbock, TX, April 2002.


Page 71 August 2016

Co-chair: Consensus Conference to Develop Guidelines for the Prevention, Diagnosis, and Treatment of Osteoporosis in the Mentally Retarded. Texas Department of Mental Health and Mental Retardation, Austin, TX, June 2002. Chair: Panel on Substance Abuse Disorders Co-occurring with Schizophrenia. Consensus Conference on Substance Abuse Co-occurring with Other Mental Disorders. Texas Department of Mental Health and Mental Retardation, Arlington, TX, April 2003. Facilitator, Working Group: Excellent Mental Health Care is Delivered and Research is Accelerated, Texas New Freedom Mental Health Summit, Austin, TX, October 2003. Co-Chair. Consensus Conference on Mental Health, Ethnicity, and Pharmacogenetics. Texas Department of Mental Health and Mental Retardation, Houston, TX, March 2004. Co-chair. Attention Deficit Hyperactivity Disorder Expert Consensus Conference, Texas Department of State Health Services, Dallas, TX, September 2004.

Scientific Program Chair, 16th Annual University of Texas Psychiatric Pharmacotherapy Update, University of Texas College of Pharmacy, Austin, TX, October 2004.

Scientific Program Chair, 17th Annual University of Texas Psychiatric Pharmacotherapy Update, University of Texas College of Pharmacy, Austin, TX, September 2005. Symposium Chair, The Burden of Mental Disorders on Care: Implications for MCOs in 2006 and Beyond. 18th Annual Meeting of the Academy of Managed Care Pharmacy, Seattle, WA, April 2006.

Rapporteur, How should services be organized and communication structures be set up? Invitational conference entitled: Where Katrina Took Us, Where Are We Now, and Where Should We Be Headed. Children’s Health Fund and Columbia University, New Orleans, LA, May 2006. Co-chair. Major Depressive Disorder Expert Consensus Conference, Texas Department of State Health Services, Dallas, TX, September 2006. Scientific Program Chair, 18th Annual University of Texas Psychiatric Pharmacotherapy Update, University of Texas College of Pharmacy, Austin, TX, October 2006. Moderator. AACP COD Special Educational Session: Pharmacy Education in a Transformed Health Market. AACP Annual Meeting, Kissimmee, FL, July 2012. Moderator. Engaging Community Practice Partners. AACP Interim Meeting, Crystal City, VA, February 2014. Moderator, Council of Deans Special Session: Selecting Academic Pharmacy Leaders: How to Get it Right, and What to Do When You Get it Wrong. AACP Annual Meeting, Grapevine, TX, July 2014


Page 72 August 2016

Facilitator, Deans Networking Session: Examination, Discussion, and Suggestions on the Proposed ACPE Standards Revision 2016. AACP Annual Meeting, Grapevine, TX, July 2014. Facilitator, Changing Practice Through Teams and Partnerships. 2015 AACP Interim Meeting, Austin, TX, February 2015. Moderator, Current and Future Trends in Community Practice. 2015 AACP Interim Meeting, Austin, TX, February 2015. Chairperson, Breakthroughs in technology and approach. Dubai International Pharmaceuticals & Technologies Conference (DUPHAT), Dubai, UAE, March 2015. Moderator, Pharmacies: the face of neighborhood healthcare. Lunch and Learn Program. Texas State Capitol, Austin, TX, April 2016. Moderator, Leadership Panel: the future of healthcare. Hospital Pharmacy Practice Seminar, Houston, TX, June 2016.

PROFESSIONAL ORGANIZATIONS Accreditation Council on Pharmacy Education (ACPE) Member, Accreditation Site Visitor Team, 2010 – present

Invited member, Advancing quality in pharmacy education: Charting accreditation’s future. Atlanta, GA, September 2012

American Association of Colleges of Pharmacy (AACP) Program Committee, Section of Teachers of Pharmacy Practice, 1987 Academic Affairs Committee, 1988 - 89 Committee on Quality of Teaching, Council of Faculties, 1989 -90

Task Force on Certificate and Nontraditional Programs, Section of Teachers of Pharmacy Practice, 1990-91

Research and Graduate Affairs Committee, 2000 - 01 Faculty delegate, 1991, 2005 - 06 Professional Affairs Committee, 2006 - 07 Advocacy Committee, 2007 - 08 Chair, Research and Graduate Affairs Committee, 2008 - 09 National Dean Facilitator, AACP Leadership Fellows Program, 2009 - 10 Member, Scientific Advisory Committee, 2011 - 12

Chair, Council of Deans Taskforce Addressing the Impact of Healthcare Reform on Pharmacy Education, 2011 – 12 Dean Delegate to House of Delegates, 2007 – 16 Chair-elect, Council of Deans, 2012 – 2013 Chair, Council of Deans, 2013 – 14 Member, Board of Directors, 2012 – 15 Member, Strategic Planning Committee, 2012-13; 2014-15 Immediate Past Chair, Council of Deans, 2014-15 Member, Investment Committee, 2014-15


Page 73 August 2016

Chair, Council of Deans Nominations Committee, 2015 Member, Institutional Research and Assessment Committee, 2015-17.

American College of Clinical Pharmacy (ACCP) Educational Affairs Committee, 1987-88 Chairman, Educational Affairs Committee, 1988-89 Budget and Finance Committee, 1989-90. Item writer, Board Certification Examination in Pharmacotherapy, 1990-91 Vice-chairman, Long Range Planning Committee, 1990-91 Chairman, Long Range Planning Committee, 1991-92 Elected Fellow, 1993. Task Force on Subspecialization, 1994 Fellowship Review Committee, 1997-99 Chair, Program Committee, 2001 Annual Meeting Member, ACCP/ASHP Taskforce on Residency Accreditation, 2002-04. Board liaison, Research Affairs Committee, 2002-05 Board liaison, CNS PRN, 2002-05 Board liaison, Clinical Administration PRN, 2002-05 Member, Board of Regents, 2002-05 Member-at-large, Executive Committee, 2003-05 Chair and Board liaison, Nominations Committee, 2003-05 Organizational Affairs Committee, 2007-08 Clinical Practice Affairs Committee, 2008-09 Slatted on the ballot for office of President-elect, 2007, 2009 Chair, Taskforce on Organizational Governance, 2010 Research Papers Award Judge, 2011 Program Committee, Annual Meeting, 1987, 2012 Nominations Committee, 2014-16

American College of Clinical Pharmacy Research Institute Member, Board of Trustees, 2010-13.

Board Liaison, Practice Based Research Network Advisory Committee, 2012-13 American Pharmacists Association (APhA) Speaker of the House, Student American Pharmaceutical Association, 1973-74 Policy Committee on Professional Affairs, 1982-83 Policy Committee on Scientific Affairs, 1985-86, 1987-88 Working group on fluoxetine and suicide, 1990. ad hoc Advisory Group on the Board of Pharmaceutical Specialties, 1994.

Panelist, Psychiatric Disorders, APhA Guide to Drug Treatment Protocols: A Resource for Creating & Using Disease-Specific Pathways, 1996. Delegate, APhA Annual Meeting, House of Delegates, 1974, 1982-86, 1989-90, 2014-16. Member, Strategic Planning Committtee, JAPhA, 2014. Member, Editorial Board, Journal of the American Pharmacists Association (JAPhA), 2014 - present.

APhA Academy of Pharmaceutical Research and Science (APRS)


Page 74 August 2016

Executive Committee Member-at-Large, APRS Section on Clinical Sciences, 1989- 90

APRS Awards Committee, 1989-90 APRS Publications Committee, 1990-91 American Public Human Services Association Member, Pediatric Psychopharmacology Working Group, 2001-2002 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Ethics Committee, 1995-2000 American Society of Clinical Psychopharmacology (ASCP) Member, 2014 Member, Awards Committee, 2015 – present Member, Annual Meeting Program Committee, 2015 - present American Society of Health-System Pharmacists (ASHP)

Consultant (Legal counsel concerning proposed revisions in Physician Labeling for Neuroleptic Drugs, 45 F.R. 52931) 1980

Delegate, South Central Clinical Conference, 1987 Project Leader, Task Force on Specialty Recognition of Psychopharmacy Practice, 1991 - 1994.

Delegate, House of Delegates, 1994-96. Member, Advisory Committee, Joseph A. Oddis Ethics Colloquium, 1998-99 Site reviewer, Psychiatric Pharmacy Residency Programs Accreditation, 2006 ASHP Foundation Literature Awards Selection Committee Member, Commission on Goals, 2011-12 ASHP Psychopharmacy Specialty Practice Group Ad Hoc Survey Task Force, 1980-81 Working Group on Education and Training, 1982-83 Working Group on Contemporary Practice, 1984-85 Nominations Committee, 1986-87

Chairman, Panel on Need: Task Force for Recognition of Psychopharmacy as a Specialty, 1986-91

Chairman, Education and Programming Committee, 1990 Vice chairman, 1990 Chairman, 1991 Austin Area Society of Health-System Pharmacists (AASHP) President-elect, 1981-82 President, 1982-83 Annual Seminar Committee Chairman, 1981 -1984 Co-Chairman of Program Committee, Annual Seminar, 1986 Board of Pharmacy Specialties (BPS) Member, Task Force on Program Operations and Process, 1994 ex officio member of the Board, 1994-97


Page 75 August 2016

Chairman, Specialty Council on Psychiatric Pharmacy Practice, 1994-96 Member, Specialty Council on Psychiatric Pharmacy Practice, 1994-97 Member, Employer Advisory Committee, 2016 College of Psychiatric and Neurologic Pharmacists (CPNP) Founding Member, 1998 Member, Public and Professional Affairs Committee, 1998-99 Member, Regional Programming Taskforce, 2001-03 Member, Program Committee, CPNP Annual Meeting, 2005. Chair, Taskforce on Revision of Psychiatric Pharmacy Residency Standards, 2006-07. National Alliance for the Mentally Ill Member National Community Pharmacists Association Member, 2007 – present National Institute for Pharmaceutical Technology & Education (NIPTE) Member, Board of Directors, 2016 Member, Advocacy Committee, 2016 National Pharmaceutical Association Member, 2008 - present Pharmacy Council on Mental Health Member, Board of Directors, 1992-1994 SACNAS Life member Texas Health Improvement Network Member, Advisory Council, 2016 – present Texas Pharmacists Association (TPA) Task Force on Clinical Practice, 1982-83 Task Force on Women in Pharmacy, 1982-83 Program Committee, Section of Consultant Pharmacists, 1983-84 Task Force on Supportive Personnel, 1983-84 Council on Professional Affairs, 1982-85 (Vice-Chairman 1984-85) Advisory Committee on Clinical Practice, 1984-85 ad hoc Advisory Group on Credentialing of Community Pharmacists, 1994 Taskforce on Scope of Practice, 2010-11 Texas Society of Health-System Pharmacists (TSHP)

Seminar Coordinator, TDMHMR-TSHP Mental Health Pharmacists Seminar, August 1984

Chairman, Council on Professional Affairs, 1983-84. Task Force on Reimbursement, 1983-84


Page 76 August 2016

Vice-Chairman, Council on Professional Affairs, 1982-83; 1984-85 Chairman, Council on Legislative and Liaison Affairs, 1986-87 Member of Board of Directors, 1981-84; 1986-89; 1992-95 Treasurer, 1987-89 Chairman, Finance Committee, 1987-89 Executive Committee, 1987-89, 1992-95 Task Force on State Legislative Planning, 1989-90 Annual Seminar Committee, 1990-91 President-elect, 1992-93 Chairman, Task Force on Revenue Enhancement, 1992-93 President and Chairman of the Board, 1993-94 Immediate Past President, 1994-95 Chairman, Nominations Committee, 1995 Legislative and Regulatory Affairs Initiatives Committee, 1995-96; 2005-07

TSHP Research and Education Foundation Treasurer, 1989-91 President, 1992-93 Vice president, 1994-95 Co-chairman, Scholarships, 1996 Member, Board of Directors, 1989-91, 1992-93, 1994-98

United States Pharmacopoeia Member, Psychiatry Expert Committee, 2006-10 Miscellaneous: Student Liaison Committee, National Pharmaceutical Council, 1973-74 Executive Committee (Student Member), Oklahoma Pharmaceutical Association, 1973 Legislative Committee, Oklahoma Pharmaceutical Association, 1973-74

Educational Leader, Soviet-American Hospital Pharmacy Clinical Study Tour, April 1984

Member, Phi Delta Chi Pharmacy Fraternity Member Rho Chi Pharmacy Honor Society Member, Texas Pharmacy Practice Coalition, 1992-95 Member, Texas Pharmacy Congress, 1992-94; 2007 - present Member, Phi Lambda Sigma National Pharmacy Leadership Society, 1995 - present UNIVERSITY ACTIVITIES The University of Texas at Austin or UT System Committees Chaired Student Health Committee, 1988-89 Institutional Review Board for Protection of Human Research Subjects, 1989-91. Research Policy Committee, 2005-06 Co-chair, Search Committee, Director of the Dell Pediatrics Research Institute, 2008.


Page 77 August 2016

Chair, ad hoc Consultative Committee for Dean of Nursing Search, 2009-10. Co-chair, Curriculum Oversight Committee, Dell Medical School, 2013 –2014. Committee Memberships

Dr. Crismon has served as a member of 25 different university system, university-wide committees or task forces, including the following:

Pharmacy Benefits Advisory Committee, University of Texas System Office of Health Affairs, 2001-05

Institutional Review Board for Protection of Human Research Subjects, 1985-2005 Institutional Review Board Accreditation Self Study Committee, 2004-05. Programming Committee, Dell Pediatrics Research Institute, 2006 Equipment Subcommittee, Dell Pediatrics Research Institute, 2006 Research Policy Committee, 2004-08 University Representative, Central Texas Institute for Research and Education in Medicine and

Biotechnology (CTI), 2005-09. Member, Advisory Committee for the 4th Annual Michael & Susan Dell Lectureship in Child

Health & Social & Environmental Solutions to Obesity Conference, The University of Texas School of Public Health, 2010

Member, Executive Compliance Committee, 2009-11 Member, Search Committee, Director of the Office of Technology Commercialization, 2013 Member, Steering Committee for Development of the Dell School of Medicine, 2013 Member, Director of University Compliance Services Search Committee, 2013 Member, ad hoc Consultative Committee for the Inaugural Dean Search, Dell Medical School,

2013 Member, Technology Commercialization Committee, 2013 Member, Ad Hoc Building Committee for the Dell Medical School Education and

Administration Building, 2013 - 14 Member, Bioethics Working Group, Dell Medical School, 2014. Member, ad hoc Consultative Committee for Chair, Department of Medicine, Dell Medical

School, 2014-15. Member, Strategic Information Technology Accountability Board, 2013 – 15 Member, Steering Committee on Social Medicine, 2014-16. Member, ad hoc Consultative Committee for Chair, Department of Psychiatry, Dell Medical

School, 2015. Member, ad hoc Consultative Committee for Dean, McCombs School of Business, 2015. Member, Campus Carry Advisory Committee, 2015 Member, Deans’ Council, 2007 – present Member, UT System Steering Committee for Transformative Initiatives in Medical Education

(TIME), 2010 – present Member, Advisory Council, Texas State Health Improvement Network (THIN), 2016 –

present. Other Activities Faculty Fellow, Division of Housing and Food Service, University of Texas, Austin, Texas,

1987-88


Page 78 August 2016

Faculty Mentor, University of Texas Honors Colloquium, 1985-86, 1989-92. Member, University Council, 2004-06. Member, Faculty Grievance Pool, 2004-06. Dean Chair, Explore UT, 2013 COLLEGE ACTIVITIES

Committees Chaired Admissions Committee, 1981-85 Honors Program Task Force, 1985-86 Accreditation Self-Study Subcommittee on B.S. curriculum, 1988-89 Subcommittee to Evaluate Student Activities in the UT Student Health Center, 1989 Faculty Retreat Committee, 1990 ad hoc Committee for Development of Austin/Temple Clinical Programs, 1991 Curriculum Committee 1986-88, 1990-92 Task Force on Curriculum, 1990-92 Ethics in Teaching and Research, 1998-2000 Ad hoc Committee to Evaluate the Dean, 2003-2004 Departmental Review Committee on Human Research, 1994-2005 Co-chair, Faculty Development Committee, 2004-06 Post Pharm.D. Training Committee, 2004-06 Subcommittee #1, College Accreditation Self Study, 2009-10 Dean’s Cabinet, 2008 – present

Committee Memberships Dr. Crismon has served on 46 different College committees , ad hoc committees, or task forces, including the following:

Library Services Committee, 1997-2005

Post-tenure Review Committee, 2001-2002 Ethics in Teaching and Research, 1998-2000; 2002-2004 Senior Staff Committee, 2005-2006 Post Pharm.D. Training Committee, 2002-2006 Graduate Studies Committee, 1981-present Departmental Review Committee on Human Research, 1994-2006 Executive Committee, 2001-2007 Program Assessment Team, 2003-2007 Honors Program & PharmD/PhD Oversight Committee, 2002-2007 Committee on Committees, 2004-2007 Conference Planning Committee, Annual Psychiatric Pharmacy Update, 1998-present Graduate Studies Administrative Subcommittee (ex officio), 2005-07. Pharmacy Residencies Committee (ex officio), 2006-07. Faculty Awards and Development Committee (ex officio), 2006-07. Strategic Planning Committee, 2009

PROFESSIONAL PRACTICE ACTIVITIES


Page 79 August 2016

Austin State Hospital, Austin, Texas:

Drug Utilization Review Committee, 1981-83 Pharmacy and Therapeutics Committee, 1981-83 Coordinator, Clinical Pharmacology and Therapeutics Course, Psychiatry Residency Program, 1981-88

Consultant, External Review of Pharmacy Services, 1990-91. Ethics Committee, 1996 Research Committee, 1981-2001 Faculty Member, Clinical Pharmacology and Therapeutics Course, Psychiatry Residency

Program, 1981-2003 Brackenridge Hospital, Austin, Texas Search Committee for Director of Pharmacy, 1991 Charter Lane Hospital, Austin, Texas: Pharmacy and Therapeutics Committee (ex officio), 1987-88 Quality Assurance Committee (ex officio), 1987-88 Healthcare Rehabilitation Center, Austin, Texas Ethics Committee, 1990-1994 Longhorn Village, Austin, Texas Member, Advisory Board, 2011 Member, Board of Directors, 2014 - present Research Consultants Review Committee, Austin, Texas:

Institutional Review Board for Protection of Human Research Subjects, 1985-89 Seton Medical Center, Austin, Texas Interview team for Director of Pharmacy search, 1990 Building Expansion Planning Committee, 1990 Seton Shoal Creek Hospital, Austin, Texas:

Pharmacy and Therapeutics Committee (ex officio), 1983-84 Member of Clinical Faculty, Psychiatry Residency and Child Psychiatry Fellowship

Programs Texas Department of Family and Protective Services Member, Advisory Committee on Psychotropic Medications, 2004 Pro bono Consultant, 2007 - present Texas Department of State Health Services Member, Texas Adolescent Mental Health in Primary Care Initiative, 2004 Texas Department of State Health Services Ad hoc working group on psychotropic guidelines for foster children, 2004. Clinical psychopharmacology consultant, 1995 – present.


Page 80 August 2016

Chair, Institutional Review Board for Protection of Human Research Subjects, Behavioral Health Committee, 2004 – 2008

Texas Department of Health and Human Services

Consultant, Treatment guidelines and quality improvement in Texas Medicaid managed care, 1999 - 2004

Member, Geriatric Prescribing Taskforce, 2001-03

Texas Department of Mental Health and Mental Retardation Central Office, Austin, Texas: Task Force on Life-sustaining Treatment, 1987-88 Task Force on Prescribing of Psychoactive Drugs in Mentally Retarded Clients, 1988 Psychotropic Medication Rule Working Group, 1989-90 Drug Use Audit Guidelines Work Group, 1990 Resource person, Unit Dose Steering Committee, 1990 Executive Formulary Committee (ex officio), 1984-91 Mental Health Workgroup on Cost of Outside Medical Care, 1993 Research Rules Revision Committee, 1995. Member, Consensus Panel on Major Depression Preferred Practices, 1996 Member, Medical Advisory Committee to the TDMHMR Board of Directors, 1992-98 Vice chairman, Medical Advisory Committee to the TDMHMR Board of Directors, 1993-

98 Public-Academic Liaison Group, 1990-99 Member, Medication Operations Committee, 1997-99 Co-Director, Texas Medication Algorithm Project (T-MAP), 1996-present Director, Children’s Medication Algorithm Project, 1998-present Clinical Psychopharmacologist, Office of the Medical Director, 1997-present Member, State Research Rule Revision Committee, 2001 Ex officio member, State Medical Records Committee, 2001 Chair, Central Office Institutional Review Board for Protection of Human Research

Subjects, 2002-04. USPHS Indian Hospital, Winslow, Arizona, 1975-76: Pharmacy and Therapeutics Committee Infection Control Committee Drug Utilization Review Committee

HONORS AND AWARDS University Scholars Scholarship, 1969-70 University of Oklahoma (O.U.) Alumni Foundation Scholarship, 1970-71 John Roberts Award for Excellence, 1971-72 American Foundation for Pharmaceutical Education Grant, 1971-72 McKesson-Robbins Leadership Award, 1973 Student American Pharmaceutical Association (SAPhA) Award for Outstanding Service to

O.U. SAPhA Chapter, 1973 Big Man on Campus, O.U., 1972-73, 1973-74 Rho Chi National Pharmacy Honor Society, 1972-74 Who's Who Among Students in American Colleges and Universities, 1973-74


Page 81 August 2016

Letzeiser Silver Medal for Scholarship and Leadership, 1973-74 Pe-et (Top ten senior men at O.U.), 1974 Humanities Seminar for Health Care Teachers Award, National Endowment for the

Humanities, 1981 Outstanding Young Men of America, 1981 Regents Fellow in Psychiatric Pharmacy, U.T. College of Pharmacy, 1985-86

Pharmaceutical Manufacturers' Association Coordinated Industry Program for Pharmacy Faculty, 1987

Nominated for Texas Exes Teaching Excellence Award, U.T. College of Pharmacy, 1982, 1990.

Fellow, American College of Clinical Pharmacy, 1993 Outstanding Research Poster Award (co-author with Stanislav SW), 13th Annual National

Symposium of the National Head Injury Foundation, 1994. Outstanding Poster Award (co-author with Lee JW, Canales PL, Dorson PG), Texas Society of

Health-System Pharmacists 49th Annual Seminar, Austin, Texas, 1997. Robert G. Leonard Memorial Lecture Award, Texas Society of Health-System Pharmacists and

The University of Texas College of Pharmacy, April 2001. Philip C and Ethel F Ashby Endowed Lecture Series Award, College of Pharmacy, The

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, February 2002.

Judith Saklad Lecture Award, College of Psychiatric and Neurologic Pharmacists, CPNP Annual Meeting, Seattle, WA April 2002.

TMAP was featured in President’s New Freedom Commission on Mental Health, Achieving the Promise: Transforming Mental Health Care in America. Final Report. DHHS Pub. No. SMA-03-3832. Rockville, MD: 2003, as an “example of an evidence based program that works.”

Southwestern Drug Corporation Centennial Fellow in Pharmacy, UT College of Pharmacy, 1986 – 2004.

Mentor for seven recipients (Eggert AE, 1995; Still DJ, 1995; Baumgartner JL, 2002; Bettinger T, 2002; Patel N, 2004; De Leon A, 2005; Gibson A, 2007) of the National Institute of Mental Health's New Clinical Drug Evaluation Unit (NCDEU) New Investigators Award.

Faculty member in the clinical psychopharmacology course chosen as 2008 Teacher of the Year by the Psychiatry Residency Program, Austin Medical Education Programs, Seton Health Network, May 2008.

Behrens Inc. Centennial Professor in Pharmacy, UT College of Pharmacy, 2004 – present. James T. Doluisio Regents Chair in Pharmacy, UT College of Pharmacy, 2007 – present. Outstanding Alumnus, The University of Texas chapter, Phi Lambda Sigma National

Pharmacy Honor Society, 2008 Distinguished Alumnus Award, College of Pharmacy, The University of Oklahoma Health

Sciences Center, 2009 Teacher of the Year, Child and Adolescent Psychiatry Residency Program, The University of

Texas Southwestern Medical Center at Austin, June 2010. First Tennessee Chair of Excellence Distinguished Visiting Professor, College of Pharmacy,

The University of Tennessee Health Sciences Center, Memphis, TN, April 2011. Alpha Alpha of Rho Chi Lecture Award, School of Pharmacy and Health Professions,

Creighton University Medical Center, Omaha, NE, February 2016. COMMUNITY ACTIVITIES


Page 82 August 2016

Member, Sub-committee on Health Legislation, Regional Health Planning Advisory

Committee, CAPCO, 1985 Vice-chairman, Regional Health Planning Advisory Committee, Capital Area Planning Council

(CAPCO), 1985-88 Member, Board of Directors, Alzheimer's and Related Disorders Association, Austin, Texas,

1993-95. Member, Mental Health Association in Texas Member, National Alliance for the Mentally Ill Member, First Unitarian Universalist Church, Austin, TX Member, Austin Chamber of Commerce PERSONAL INFORMATION

Place of Birth: Tulsa, Oklahoma Married: Jeanette Wickwire Crismon Home Address: 9600 Murmuring Creek Dr. Austin, Texas 78736

Children: Teresa Lynne Crismon Anthony Edward Crismon Adriana Arispe Olya Grace Crismon Alexander M. Arispe Sergey Alexander Crismon

Documents

M. Lynn Crismon, Pharm.D., FCCP, BCPP OFFICE ADDRESS …sites.utexas.edu/crismon/files/2015/03/Crismon-CV-160821.pdf · CURRICULUM VITAE M. Lynn Crismon, Pharm.D., FCCP, BCPP OFFICE